



BIOGIPUZKOA

EUSKAL
OSASUN
IKERKUNTZA
INVESTIGACIÓN
VASCA
EN SALUD
BASQUE
HEALTH
RESEARCH

Scientific Report 2025



Osakidetza



EUSKO JAURLARITZA
GOBIERNO VASCO

OSASUN SAILA
DEPARTAMENTO DE SALUD

Scientific Report 2025




BIOGIPUZKOA

EUSKAL
OSASUN
IKERKUNTZA
INVESTIGACIÓN
VASCA
EN SALUD
BASQUE
HEALTH
RESEARCH



Table of Contents



1

Presentation
06

2

Organisation
08

3

Platforms
12

4

**Main
Milestones of
Biogipuzkoa
HRI 2024**
28

5

**The
Biogipuzkoa
HRI in figures**
32

6

**Research
Areas and
Groups**
46

7

**Financial
Data**
126

8

Innovation
130

9

Communication
134

10

BG Zurekin
138

Presentation



**Itziar Vergara
Micheltoarena**

Scientific
Management

*It matters not how strait the gate,
How charged with punishments the
scroll,
I am the master of my fate,
I am the captain of my soul.*

William Ernest Henley

The 2025 annual report is not just another report. It corresponds to the final year of the Strategic Plan cycle and, as such, provides a good example of the ability that plans often have to guide our work. The plan that this annual report brings to a close focused on four areas of action: translational research, innovation and medical technology, management and infrastructure, and internationalization.

Throughout 2025, all of us at Biogipuzkoa HRI have continued to work toward advancing these proposed areas, and the truth is, we have succeeded. We have increased the number of grants secured through competitive calls for proposals and the funding obtained; we have improved our workspaces and the infrastructure that supports us; and all of this has enabled us to generate new knowledge and innovation that has an impact on three levels: in the scientific sphere, with an increase in the number and quality of our publications; in society, with more news coverage and publications, as well as an increase in the number of activities and projects shared with the public; and, above all, for patients.

This year, we're highlighting a few milestones because they exemplify what it means to conduct translational research—that is, to have an impact on patients. We bring the knowledge generated by our multidisciplinary teams closer to patients and the healthcare system. And we do so through national and international collaboration.

I would like to highlight the SEEDs-ALS project, led by Dr. López de Munain in the Neuroscience Division, which aims to deepen and improve the approach to ALS; the ClickCART project for the development of a new generation of CAR therapies; the CARMEL project, which, from the perspective of digital innovation and primary care, addresses cardiovascular health in perimenopausal women; and the new family of therapies for cholangiocarcinoma developed in collaboration with Ikerbasque, the University of the Basque Country (EHU), and the DIPC through the Liver Diseases Division. In addition to these notable projects, we are pleased to announce that young researcher Dr. Leire Bejarano has been awarded a grant through the ERC Starting Grant program and has joined the Oncology Division, as well as the recognition of the work and career of Dr. Amaia Cipitria, coordinator of the Bioengineering Division, with the Constantes Vitales Award.

This year, I cannot deny that we face major challenges along the way. But our determination, steadfast work, and teamwork make us the captains of our own souls.

Organisation

The Biogipuzkoa HRI has the following organisational structure:

- **General Assembly**
- **Executive Committee**
- **Management Committee**
 - Scientific Management**
Dr Itziar Vergara Mitxeltorena
 - Management Directorate**
Dr Arantza Abad Alba
 - People and Finance Directorate**
Amaia Pedruzo Suso
 - Strategy and Impact Directorate**
Dr Olatz Arrizabalaga Garde
- **Extended Management Committee**
 - Clinical Research Unit**
Dr Ioana Riaño Fernández
 - Platforms and Infrastructure**
Dr David Otaegi Bichot
 - Project Unit**
Marisabel Arzamendi Sesé
- **External Scientific Committee (ESC)**
- **Internal Scientific Committee (ISC)**

Organisation



To carry out its activities, the Biogipuzkoa HRI has **nine R&D&I Support Units** staffed by qualified personnel responsible for the institute's management functions:

- 1. Economic and Administrative Unit
- 2. Purchasing and Public Procurement Unit
- 3. Human Resources (HR) Unit
- 4. Project Unit
- 5. Innovation Support Unit (ISU)
- 6. Evaluation and Quality Unit
- 7. Scientific Coordination Unit
- 8. Communication Unit
- 9. Scientific Outreach and Culture Unit
- 10. OSH Coordination Unit
- 11. General Services Unit

In addition, the Biogipuzkoa HRI has **three R&D&I Support Services** staffed by professionals qualified to provide scientific advising services, primarily in research methodology, each coordinated by a designated manager:

- 1. Methodological Support Service
- 2. Clinical Epidemiology Service
- 3. Primary Care Service and IHOs

Lastly, the Biogipuzkoa HRI has **nine R&D&I Support Platforms** staffed with qualified personnel and equipped with the necessary infrastructure for specialised techniques. These platforms offer technical and scientific support to the institute's researchers, as well as to research centres, technology centres and external companies. The aim of these platforms is to promote biomedical research by providing scientific infrastructure and qualified personnel:

- 1. Animal Facility and Experimental Operating Theatre (PAQE)
- 2. Computational Biology
- 3. Cell Cultures
- 4. Molecular Diagnosis
- 5. Genomics
- 6. Histology
- 7. Multidisciplinary 3D Printing Platform (3DPP)
- 8. Clinical Research (CRP)
- 9. Basque Biobank Node

Platforms




The purpose of the **nine R&D&I Support Platforms at the Biogipuzkoa HRI** is to boost biomedical research by offering users scientific infrastructure and expert personnel in highly complex techniques or those requiring costly or sophisticated equipment.

A total of 40 professionals make up the R&D&I Support Platforms, some of whom work across multiple platforms.



Platforms



Animal Facility and Experimental Operating Theatre

This facility provides a modern environment for working with animals, ensuring full compliance at all times with Royal Decree 53/2013 of 1 February.

Activity Indicators

- 33 R&D&I projects reviewed by the Animal Experimentation Ethics Committee (AEEC)
- 43 R&D&I projects reviewed by the Authorised Body (AB)
- 18 services provided in 2025 (13 internal and 5 external)
- 105 training activities delivered in 2025 (20 on large animals, 29 on small animals and 66 on anatomical specimens)
- 9 courses organised in 2025 (1 with large animals and 8 with specimens)

plataforma.animalario@
bio-gipuzkoa.eus

In 2025, the Animal Facility and Experimental Operating Theatre remains part of the ISCIII Biobanks and Biomodels Platform and committed to the *Transparency Agreement on the Use of Animals in Scientific Experimentation* in Spain, promoted by the Spanish Confederation of Scientific Societies (COSCE). The aim is to establish communication channels between the scientific community and society to explain when, how and why animals are used in research, and to highlight the benefits of this practice. It is also part of the Spanish Animal Welfare Network

Services include advising and support in experimental techniques, assistance in designing R&D&I projects, ensuring animal welfare, running training courses on various techniques and organising events for continuing education.

The platform also coordinates the teaching activity of Donostialdea IHO.




The platform is staffed by seven professionals

3.1

Computational Biology

The platform offers a portfolio of services in data processing for projects in the field of personalised precision medicine.

During this year, the platform has been undergoing review and reformulation.



3.2

Cell Cultures

It provides technical and scientific assistance in areas such as cell cultures (cell amplification, cryopreservation, immunofluorescence, etc.), fluorescence microscopy and flow cytometry.

Activity Indicators

- 151 users accessed the platform's infrastructure in 2025

The platform is staffed by five people

The Microscopy and Flow Cytometry Units not only support Biogipuzkoa researchers, but are also positioning themselves to serve biotech companies in the region.

It is certified under the ISO 9001:2015 Quality Standard.



plataforma.
cultivoscelulares@
bio-gipuzkoa.eus

3.3

Molecular Diagnosis

It conducts a range of molecular studies on hereditary diseases, primarily within the Neuromuscular Diseases Area.

Activity Indicators

- 418 molecular diagnoses were carried out in 2025

The platform is staffed by three people

Since 2000, it has been a leading centre nationally for the genetic diagnosis of facioscapulohumeral muscular dystrophy (FSHD), receiving samples not only from Spanish hospitals and centres but also from international institutions.

It is certified under the ISO 9001:2015 Quality Standard.



plataforma.
diagnosticomolecular@
bio-gipuzkoa.eus

3.4

Genomics

It provides researchers with advising services and tools to implement the most suitable genomics and transcriptomics techniques for their biological studies.

Activity Indicators

- 53 R&D&I projects have benefited from the platform's services.

Available equipment:

- Sanger sequencing: SeqStudio (Applied Biosystems)
- Single cell: Rhapsody system with scanner (BD Bioscience)
- Real-time thermocyclers (LC96, CFX96, CFX384, CFX384 Opus)
- Digital PCR (QX200 Bio-Rad)
- Microplate readers: Haloled96 (Technical Control)
- Magpix plate readers Glonax (Biorad)
- Typhoon Biomolecular Imager (Amersham)
- Nucleotide extraction (Maxwell, Promega)
- Quantification and quality control of nucleotides (Nanodrop, Qubit, TapeStation 4150 and Quiaxcell)

NGS services:


- Gene panels (AmpliSeq)
- Metagenomic analysis (16S)
- RNAseq transcriptome analysis (totalRNAseq, mRNAseq, smRNAseq)
- Whole-Genome Sequencing (WGS)
- Single-cell sequencing
- Data analysis

It is certified under the ISO 9001:2015 Quality Standard.

plataforma.genomica@
bio-gipuzkoa.eus

The platform is staffed by three people

3.5



Histology

It offers a wide range of histopathological techniques:

- Tissue processing
- Paraffin and OCT embedding
- OCT block sectioning (cryostat)
- Paraffin block sectioning (microtome)
- Fixation and decalcification
- Routine and special stains
- Immunohistochemistry (including antibody optimisation)
- Immunofluorescence (including antibody optimisation)
- Organoid processing

It is certified under the ISO 9001:2015 Quality Standard.



Activity Indicators

- 47 internal users have requested platform services

plataforma.histologia@
bio-gipuzkoa.eus

Multidisciplinary 3D Printing Platform (3DPP)

This platform comprises two interdependent units:

- The 3D Biomodelling Unit, based at Donostialdea IHO, offers services in disease modelling (primarily tumours) to improve surgical approaches and operating times, as well as to customise prosthetic implants.
- The 3D Biofabrication Unit, based on the institute's second floor, offers services in the bioprinting of cells and tissues for use in regenerative medicine.

It is part of the Support Platform for R&D&I in Biomedicine and Health Sciences of Biobanks and Biomodels at the Carlos III Health Institute (PISCIIBB).

Staff from the 3DPP Platform served as jury members for 3D-related projects submitted to the "Donostia Innovation Challenge 2024" organised by Fomento San Sebastián.

In 2025, the 3DPP platform, which is part of ISCIII's HuB3D, also took part in the "3rd Conference of the ISCIII Platform of Biobanks and Biomodels" in Lleida.

The platform is staffed by three people

Activity Indicators

- 11 competitive projects involving the 3DPP Platform
- 16 Donostialdea IHO services using 3D technology

- 64 3D models produced by the 3D Biomodelling Unit
- 6 3D models produced by the 3D Biofabrication Unit
- Participation in technology transfer initiatives to support and enhance the competitiveness of innovative business projects ("Bono Fomento" funding instrument): 1
- Participation in innovation projects at Donostialdea IHO (bottom-up): 1

PLATAFORMA ISCIII
BIOBANCOS Y
BIOMODELOS



plataforma.biomodelado3d@
bio-gipuzkoa.eus
plataforma.
biofabricacion3d@bio-
gipuzkoa.eus

3.6

3.7

Clinical Research

1. Scientific and Technical Development Division

The team consists of 6 people, including: 2 clinical project managers, 1 data science manager, 2 monitors, and 1 methodologist.

2. Implementation, Evaluation, and Monitoring Area

The team consists of three people: the implementation coordinator, a technical-economic specialist, and an administrative assistant.

3. Implementation Support Division

It includes staff responsible for clinical trial coordination, nursing, and biological samples, for a total of 7 people, of whom 3 are study coordinators, 4 are nurses, and 1 is a biological samples technician.

The Clinical Research Platform (CRP) supports all clinical research conducted in healthcare centres belonging to the Basque Health Service (Osakidetza-SVS) in Gipuzkoa, including six hospitals and 56 primary care centres.

It also provides support to national healthcare centres for any multicentre studies that are promoted or supported.

The CRP consists of three interrelated areas, each staffed by multidisciplinary professionals who provide scientific and technical support for clinical research:

1. Scientific and Technical Development Division:

Turn an idea into a robust and competitive clinical trial. We provide methodological and scientific support for the development of clinical research projects, offering guidance and assistance with study design, protocols, informed consent, technical and operational aspects, regulatory and ethical-legal support, management of medications and medical devices, and monitoring.

2. Implementation, Evaluation, and Monitoring Area:

Strategic Feasibility and Monitoring
It encompasses the areas of management and financial administration.

- Comprehensive management of all clinical trials conducted at Osakidetza-SVS healthcare centers in Gipuzkoa and the implementation of those trials.

- Structured evaluation and prioritization.

- Coordination of contracts, authorizations, and related services.

- Comprehensive monitoring throughout the entire study lifecycle.

Activity Indicators

152 Project Leaders
101 Principal Investigators
30 Healthcare Services

1. Scientific and Technical Development Division

Number of clinical studies supported by the department: 40. Of these, 19 are drug trials, 9 are medical device studies, and 12 are research projects.

*34 coordinated health centers (nationwide)

*9 ECs managed through SCRen networks

*6 studies sponsored by IIS Biogipuzkoa

It is certified in accordance with the ISO 9001:2015 Quality Standard.

3. Implementation Support Division:

Integrate clinical research into real-world healthcare practice.

- Coordination of research and direct support for researchers.

- Patient Management, Data, Specimens, and Care Pathways.

- Nursing and specialized coordination of clinical trials, with responsibilities related to the management, collection, processing, and shipment of biological samples for clinical research.

2. Implementation, Evaluation, and Monitoring Area.

*49 clinical studies evaluated

*298 clinical studies managed and under follow-up

*2,648 patients enrolled.

3. Implementation Support Division.

*61 clinical trials coordinated by a study coordinator.

*6 clinical trials of advanced therapies in collaboration with the Advanced Therapies Unit, the Pharmacy Department, and Patient Care Services.

Number of studies supported by nursing staff for biological sample handling: 77

*1,144 visits conducted

*413 patients treated
*4,949 samples processed



osid.investclinica@osakidetza.eus

Basque Biobank Node of the Biogipuzkoa HRI

The platform is staffed by five people.

The Basque Biobank is a structure that holds biological samples associated with clinical data. These are collected, processed, stored and managed to high quality standards and made available on a not-for-profit basis to the scientific community to promote biomedical research.

It has a decentralised network structure with nodes located in the main Osakidetza-SVS centres.

The Basque Biobank Node at the Biogipuzkoa HRI consists of two units: tissue and DNA.

The following services are offered:

- Collection, storage and delivery of biological samples prospectively obtained in accordance with the criteria of an R&D&I project
- Creation of strategic sample collections from diagnostic surpluses for future projects
- Provision of stored samples from the Basque Biobank to R&D&I projects All types of samples are stored, primarily oncological and neurological tissue and blood-derived samples from various diseases, for the extraction of products such as serum, plasma, DNA, RNA, cells, etc.
- Advising on all aspects related to the collection, processing and provision of biological samples (ethical and legal framework)

The Basque Biobank has a real-time updated catalogue of available samples and data organised by pathology. To access samples, researchers must have a research project approved by an ethics committee and submit the relevant request.

Activity Indicators

- The node managed 559,128 samples, of which 51,389 were collected in 2025, either as diagnostic surpluses or within research projects, with the prior informed consent of the donor
- It has served more than 180 depositories. All kinds of samples have been received (blood, tissue, urine, cerebrospinal fluid, saliva, etc.) mainly related to oncological and neurological conditions, as well as follow-up tests and respiratory diseases.
- 98 sample requests associated with R&D&I projects were processed, 29 of which were received in 2025

It is part of the R&D&I Support Platform in Biomedicine and Health Sciences of Biobanks and Biomodels at the Carlos III Health Institute.



- More than 26,000 samples from various pathologies have been processed, notably those related to multiple sclerosis, Steinert's myotonic dystrophy, lymphomas, HIV, melanoma, cholangiocarcinoma, etc. As well as population-based collections: INMA Cohort, IMPaCT Cohort and Frail Elderly Cohort.

65% of the samples supplied were linked to R&D&I projects requiring prospectively organised collection.



donostia.
biobancovasco@bioef.
eus

Main Milestones of the Biogipuzkoa HRI



Main milestones of the Biogipuzkoa HRI 2025

01. **ERC STARTING GRANT - LEIRE BEJARANO**

Leire Bejarano, head of the Brain Tumors group, has been awarded an ERC STARTING GRANT worth 1,499,500 euros to develop the METAVASC project. This project takes an innovative approach to studying the role of vascular components in the early and advanced stages of brain metastasis, with the goal of translating this knowledge into clinical practice.



02. **CLICK CAR PROYECT**

Click-CAR aims to drive the development of a new generation of CAR-T therapies. This technology will enable the design of more personalized and effective treatments, reducing side effects and simplifying their production.



03. **SEED ALS - ADOLFO LÓPEZ DE MUNAIN NATIONAL PI**

A multicenter project that brings together most of the groups working on amyotrophic lateral sclerosis (ALS) throughout the country. SEED-ALS aims to foster the convergence of research efforts on ALS in Spain in order to answer key questions for understanding the development and origin of this disease.



04. **AMAIA CIPITRIA - CONSTANTES Y VITALES AWARD**

Amaia Cipitria, an Ikerbasque researcher and head of the Bioengineering area and the Bioengineering in Regeneration and Cancer Group, has been awarded the Constantes y Vitales Prize for Young Talent in Biomedical Research, which comes with a cash prize of 100,000 euros to enable her to continue with one of the group's main lines of research: the latency of metastatic breast cancer.



05. **CARMEL STUDY**

A research project funded by the EU's Horizon Europe programme. The consortium brings together various research institutions, hospitals, and small and medium-sized enterprises, with 25 partners across 11 countries. The aim of the project is to develop advanced models for assessing cardiovascular risk, as well as digital tools, to empower women between the ages of 40 and 60 to actively manage their cardiovascular health.



06. **CHOLANGIOCARCINOMA - A NEW THERAPEUTIC APPROACH**


A multidisciplinary team from IIS Biogipuzkoa, affiliated with the Department of Health, and Osakidetza, in collaboration with the University of the Basque Country (EHU) and the DIPC, has developed and patented a new chemotherapy formula that has demonstrated remarkable efficacy against an aggressive form of liver cancer with a very poor prognosis, known as cholangiocarcinoma.



The Biogipuzkoa HRI in figures

5





Resources

Research staff: annual evolution

165

Research staff fully or partially funded through competitive calls and networks

The Biogipuzkoa HRI has formally adopted the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers (C&C).

By category, the Biogipuzkoa HRI's Research Groups are made up of 504 researchers. Of these, 446 correspond to the R1, R2, R3 and R4 profiles according to the European EURAXESS classification scheme. The remaining 58 members of the research groups are considered support staff.

	2021		2022		2023		2024		2025	
	♂	♀	♂	♀	♂	♀	♂	♀	♂	♀
R1 PhD Student in training	23 (27%)	63 (73%)	22 (23%)	74 (77%)	24 (24%)	75 (76%)	24 (28%)	61 (72%)	23 (27%)	63 (73%)
R2 Postdoctoral Researcher	85 (43%)	112 (57%)	87 (41%)	126 (59%)	99 (39%)	153 (61%)	109 (40%)	165 (60%)	108 (38%)	178 (62%)
R3 Senior Researcher	8 (35%)	15 (65%)	8 (33%)	16 (67%)	9 (36%)	16 (64%)	8 (36%)	14 (64%)	7 (30%)	16 (70%)
R4 Area Coordination Group Manager	24 (63%)	14 (37%)	24 (62%)	15 (38%)	26 (63%)	15 (37%)	24 (53%)	21 (47%)	28 (55%)	23 (45%)

Support Units, Services, and Platforms Staff

The R&D&I Support Units are made up of 34 people in total.

- Economic and Administrative Unit
- Purchasing and Public Procurement Unit
- People Management Unit
- Projects Unit
- Innovation Support Unit
- Evaluation and Quality Unit
- Scientific Coordination Unit
- Communication Unit
- Scientific Outreach and Culture Unit
- Legal Unit
- Data Coordination Unit
- OSH Coordination Unit
- General Services Unit

A total of 55 professionals work across the R&D&I support platforms and the three common support services, some of whom also belong to the Institute's research groups.

Support Services:

- Methodological Support Service
- Clinical Epidemiology Service
- Primary Care Service and IHOs

Platforms:

- Animal Facility and Experimental Operating Theatre
- Computational Biology
- Cell Cultures
- Molecular Diagnosis
- Genomics
- Histology
- Multidisciplinary 3D Printing Platform
- Clinical Research
- Basque Biobank Node

34

R&D&I Support Units

♂9 ♀25

7

Common Support Services

♂0 ♀8

48

R&D&I Support Platforms

♂7 ♀41

Research Activity

Number of projects granted (competitive and non-competitive)

279

Total number of projects

11,188,117.65 €

Funding obtained through competitive calls

2.2


Research Area	Granted projects in 2025			Projects granted through public calls at the national and/or international level	
	Projects	Principal investigator		Projects	Principal project investigator
		♂	♀		
Neurosciences	69	11	17	17	12
Liver and Gastrointestinal Diseases	36	5	4	9	5
Infectious Diseases	5	3	0	3	1
Oncology	48	4	12	18	10
Systemic Diseases	22	3	9	4	3
Epidemiology and Public Health	26	2	14	14	7
Bioengineering	32	3	6	12	4
Total Prioritised Areas	238	31	62	77	42
Non-prioritised area	33	13	16	4	3
Units and Platforms	8	0	4	2	1

National and International Networks

	National	International
NETWORKS	• CIBEREHD • CIBERESP • CIBERFES • CIBERNED • CIBERSAM • CIBERES • RICORS ICTUS • RICAPPS • TERA+V • TEVIMO • REEM • EXONED • Spanish Duchenne Muscular Dystrophy Registry • Certera Consortium	• BTC - Cost Action CA22125 • NETSKINMODELS - Cost Action CA21108 • ADVANCETB - Cost Action CA21164 • EUNETCC • ERN - RARE LIVER • European network for the study of Cholangiocarcinoma • Human Brain Project • CINNAMONN - Cost Action CA24115 • MITGEST • BTCS4ATMP - Cost Action CA24114 • Net4Brain - Cost Action CA22103 • Max Planck Queensland Center
INFRASTRUCTURES	• IMPaCT	• ECRIN • EATRIS
PLATFORMS	• ITEMAS • BIOBANKS and BIOMODELS	

Scientific Output


PUBLICATIONS



TYPE OF COLLABORATION



LEADERSHIP




JCR 2024 data


Scientific Output List



Publications by category



Participation in conferences





Training

Undergraduate and postgraduate



Activities for residents

- 1 Visit to Biogipuzkoa
- 2 Research during residency
- 3 Projects for participation
- 4 Award for Resident Researchers



Global Clinical Studies Biogipuzkoa HRI

TOTAL number OF
STUDIES BY SPONSOR
TYPE

Commercial, 141
Scientific association or group, 45
Independent, 42
University, 4
Total 232

101

Lead investigators

Number of clinical studies started in 2025

Clinical trials with medicinal products	30
Clinical research with medical devices	4
Observational studies with medicinal products	14
Observational studies with medical devices	1
Total	49

	2021	2022	2023	2024	2025
Total clinical studies	330	319	320	314	232
Clinical trials	170	168	172	166	161
Observational studies	91	83	78	76	71

30.5%

Early-phase clinical trials out of all clinical trials with medicinal products

Type of study		Total number of studies
MEDICINAL PRODUCTS	PHASE I clinical trials	9
	PHASE II clinical trials	35
	PHASE III clinical trials	82
	PHASE IV clinical trials	18
	Observational studies with medicinal products	63
MEDICAL DEVICES	Clinical research with MEDICAL DEVICES	17
	Post-marketing observational studies with MEDICAL DEVICES	8
Total		232



Research Areas and Groups

6



6.1 Neurosciences Area

NEUROSCIENCES AREA

Illnesses
Neurodegenerative Diseases

Neuromuscular Diseases

Neuroimmunology

Mitochondria, Health & Longevity

Sensory Neurodegeneration

Mental Health and Psychiatric Care

Stroke

Neurogenetics, biology and RNA therapies - NeuroRNA

Scientific objectives and progress in 2025

The following monitoring objectives were successfully achieved during 2025:

- Integration of the various research groups within the area being coordinated.
- Promotion of research lines and intra-area collaboration.
- Translational application of research lines through collaboration between 2 or more groups in the area.
- Production of research results involving members of 2 or more groups in the area.
- Promotion of research careers within the area.

Most Notable Publications in 2025

Moles L, Konings M, Crespillo Velasco H, Bravo Miana RD, Prada A, Castillo Triviño T et al. Unraveling cholesterol metabolism in multiple sclerosis: Gender-specific patterns and predictive biomarkers. Neurobiol Dis. 2025; 217107143-107143.

Lopez Martinez A, Martin Gonzalez S, Torres Conde N, Alcala Manso N, Al Ani A, Lopez de Munain A et al. Characterization of DMPK and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening. NAR Mol. Med. 2025; 2(3):23-23.

Nunnink M, Ballester L, Vilagut G, Alayo I, Mortier P, Almenara J et al. Depression and anxiety: A 3-year follow-up study of associated risk and protective factors among university students. J Affect Disord. 2025; 391120058-120058.

Lara López A, Gonzalez Imaz K, Rodríguez Hidalgo M, Sarasola Gastesi M, Escudero Arrarás L, Milla Navarro S et al. Topical Administration of Novel FKBP12 Ligand MP-004 Improves Retinal Function and Structure in Retinitis Pigmentosa Models. Invest. Ophthalmol. Vis. Sci. 2025; 66(3):56-56.

Renu A, de la Riva P, Delgado Mederos R, Dorado L, Fernandez Couto MD, Herrera Isasi M et al. Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial: study protocol. Stroke Vasc. Neurol. 2025;



6.1.1

Neurodegenerative Diseases

AWARDED HR POSITIONS

Public competitive programmes



Release of Researchers



Scholarship

HR

Managers
Barandiaran Amillano, Myriam Jesús Ruiz Martínez, Javier

Team
Senior Researcher
Moreno Izco, Fermín

Postdoctoral Researcher
Etxeberria Arrichabal, Igone
Gereñu Lopetegui, Gorka
Jimenez Salvador, Irene
Jiménez Zúñiga, Andrés
Minguez Olaondo, Ane

Permanent Clinical Researcher
Campo Caballero, David
Fernández Pardavila, Esther
Gabilondo López, Alazne
Mondragón Rezola, Elisabet
Muñoz Lopetegui, Amaia
Tainta Cuezva, Mikel
Vinagre Aragón, Ana

PhD Student
Zuñiga Elizari, Jose Luis

Platform Manager
Gorostidi Pagola, Ana

Senior Research Technician
Alves Días, Patricia
Croitoru, Ioana Marcela


Laboratory Technician
Hernández Eguiazu, Haizea
Moragon Rodriguez, Saioa

PROJECTS

Active Projects
Public Competitive programmes
National, 1
Autonomous, 3
Total 4

Public competitive programme projects awarded
Autonomous, 2
Total 2

SCIENTIFIC OUTPUT



TRANSFER

Patent family:
1. FOXO inhibitors: A new treatment for Amyotrophic Lateral Sclerosis (ALS).
2. ALS biomarker ELOVL6.
3. Methods and compositions for the diagnosis and/or treatment of proteinopathies.
Licensing agreements:
1. FOXO inhibitors: a new treatment for amyotrophic lateral sclerosis (ALS), licensed to MIAKER DEVELOPMENTS S.L.

Start up:
1. MIAKER DEVELOPMENTS S.L.

HIGHLIGHTED ARTICLES

01. Bracher Smith M, Melograna F, Ulm B, Bellenguez C, Grenier Boley B, Duroux D et al. Machine learning in Alzheimer's disease genetics. Nat Commun. 2025; 16(1):6726-6726.
02. Planas Serra L, Rodríguez Ruiz M, Anderson EN, Rodríguez Palmero A, Vélez Santamaria V, Schlüter A et al. Bi-allelic variants in the ribosomal protein RPS6KC1 cause a complex neurodevelopmental disorder. Am J Hum Genet. 2025; 112(11):2643-2664.
03. Murueta Goyena A, Teijeira Portas S, Blanco Martin E, Vazquez Picon R, Ruiz B, Bocos J et al. Dynamics of retinal changes in early-stage Parkinson's disease. Acta Neuropathol. Commun. 2025; 13(1):20-20.

CLINICAL TRIALS

Clinical research
Clinical trials with medicinal products (MPs), 6
Clinical research with medical devices (MDs), 0
Observational studies (with MPs and MDs), 4
Total active clinical studies 10

6.1.2

Neurosciences Area

Neuromuscular Diseases

AWARDED HR POSITIONS

Public competitive programmes



Predoctoral contracts



Scholarship

HR

Managers

López de Munain Arregui, Adolfo José Saénz Peña, Miren Ametsa

Team

Senior Researcher

Gil Bea, Francisco Javier Fernández Torrón, Roberto Sistiaga Berrondo, Andone Vallejo Illarramendi, Ainara

Postdoctoral Researcher

Aizpurua Iparraguirre, Jesús María Immanuel, Jenita Labayru Isusquiza, Garazi Pan Montojo Puga, Francisco José Pérez Agustín, Adrián Zayas Arrabal, Julián

Permanent Clinical Researcher

Poza Aldea, Juan José

PhD Student

Garciandia Arcelus, Maddi Gonzalez Imaz, Klaudia Horcajo Arbosa, Aixa Marco Moreno, Pablo Mosqueira Marín, Laura Pascual Frías, Nerea Prendes García, Carolina Rodríguez Gómez, Laura Ruiz Roldan, Cristina Sanchez Molleda, Ángela Valls Rodríguez, Andrea

Platform Managers

Aiastui Pujana, Ana Camaño González, María Pilar

Laboratory Technician

Levchuk, Mariya

Senior Research Technician

Garay Albizuri, Patricia

PROJECTS

Active projects
Public competitive programmes

National, 7

Autonomous, 11

Active projects
Private competitive programmes

International, 1

Total 19

Public competitive
programme projects
awarded

International, 1

National, 2


Autonomous, 4

Private competitive
programme projects
awarded

National, 1

Total 8

SCIENTIFIC OUTPUT



HIGHLIGHTED ARTICLES

01.

Lopez Martinez A, Martin Gonzalez S, Torres Conde N, Alcala Manso N, Al Ani A, Lopez de Munain A et al. Characterization of DMPK and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening. NAR Mol. Med. 2025; 2(3):23-23.

02.

Moreno Martinez L, Gaja Capdevila N, Mosqueira Martín L, et al. Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1(G93A) amyotrophic lateral sclerosis (ALS) mice. Br. J. Pharmacol. 2025; 182(11):2466-2486.

03.

Launay N, Espinosa Alcantud M, Verdura E, Fernández Eulate G, Ondaro J, et al. Altered tubulin detyrosination due to SVBP malfunction induces cytokinesis failure and senescence, underlying a complex hereditary spastic paraplegia. Aging Cell. 2025; 24(1)

TRANSFER

Patent family:

1. New compounds for regulating intracellular calcium homeostasis.
2. FOXO inhibitors: A new treatment for Amyotrophic Lateral Sclerosis (ALS).
3. ALS biomarker ELOVL6.
4. Compounds for use in the treatment of limb-girdle muscular dystrophy type 2A (LGDM2A) - dihydroquinolines.
5. Compounds for use in the treatment of limb-girdle muscular dystrophy type 2A (LGDM2A) - thiadiazolidinones.
6. Triazoles for the treatment of ocular diseases.
7. Methods and compositions for the diagnosis and/or treatment of proteinopathies.

Licensing agreements:

1. New compounds for regulating intracellular calcium homeostasis (triazoles), licensed to MIRAMOON PHARMA S.L.
2. FOXO inhibitors: new treatment for amyotrophic lateral sclerosis (ALS), licensed to MIAKER DEVELOPMENTS S.L.


Spin-off:

1. MIRAMOON PHARMA S.L.

Start-up:

1. MIAKER DEVELOPMENTS S.L.

PARTICIPATION IN CONFERENCES



CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 11

Clinical research with medical devices (MDs), 1

Observational studies (with MPs and MDs), 2

Total active clinical studies 14

TRAINING



Total doctoral theses defended



Internationally recognised theses

6.1.3

Neuroimmunology

Neurosciences Area

AWARDED HR POSITIONS

Public competitive programmes



Postdoctoral contracts

HR

Managers

Otaegui Bichot, David
Castillo Triviño, Tamara

Team

Senior Researcher

Muñoz Culla, Maider

Postdoctoral Researcher

Alberro Garitano, Ainhoa
Arias González, Noelia
Bravo Miana, Rocio del Carmen
Celarain Sanz, Naiara
Gorostidi Acua, Miriam
Martínez Ascensión, Alex
Moles Alegre, Laura

Permanent Clinical Researcher

Arruti González, Maialen
Andrés Marín, Naiara
Espinosa Ros, Eduardo
Prada Iñurrategui, Alvaro

PhD Student

Arizaga Echebarria, Jone Karmele
Iribarren López, Andrea
Martins Almeida, Laura
Mendiburu Arrieta, Idoia
Otaegui Chivite, Ane
Zabala García, Aitor

Senior Research Technician

Mendiburu Arrieta, Idoia
Romarate García, Leire

Laboratory Technician

Crespillo Velasco, Hirune

PROJECTS

Active projects
Public competitive programmes

National, 1
Autonomous, 7
Local, 2


Active projects
Private competitive programmes

International, 1
Autonomous, 2
Total 13


Public competitive
programme projects
awarded

International, 1
Autonomous, 4
Local, 1
Total 5

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



TRANSFER

Patent family:

1. Circular RNAs as biomarkers of multiple sclerosis.
2. Molecular patterns for diagnosis and stratification of frail individuals.
3. Methods and compositions for the diagnosis and/or treatment of proteinopathies.

Intellectual property:

1. App for monitoring and tracking animal models.

HIGHLIGHTED ARTICLES

- 01.** Moles L, Konings M, Crespillo Velasco H, Bravo Miana RD, Prada A, Castillo Triviño T et al. Unraveling cholesterol metabolism in multiple sclerosis: Gender-specific patterns and predictive biomarkers. Neurobiol Dis. 2025; 217107143-107143.
- 02.** Iribarren López A, Martins Almeida L, Wells JK, Castillo Triviño T, Prada A, Pickett HA et al. Aging-dependent immunological changes in multiple sclerosis. Front. Immunol. 2025; 161663526-1663526.
- 03.** Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D et al. Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2025; 82(6):614-625.

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 4
Clinical research with medical devices (MDs), 0

Observational studies (with MPs and MDs), 5

Total active clinical studies 9

TRAINING



Total doctoral theses defended



Internationally recognised theses

6.1.4



Mithochondria, Health & Longevity

PARTICIPATION IN CONFERENCES

2

Presentations

2

Posters

Neurosciences Area

HR

Manager

Holt, Ian James

Team

Postdoctoral Researcher

Goikoechea Barrenechea, Leire
Muñoz Oreja, Mikel

PhD Student

Chengtai, Li
Frimpong, Angela

PROJECTS

Active projects
Public competitive programmes

National, 2

Autonomous, 2

Total 4

Projects awarded
Public competitive programmes

Autonomous, 1

Total 1

TRANSFER

Patent family:

- 1. Compounds for treating mitochondrial DNA disorders.
- 2. The Use Of Mn2+ To Alleviate Impaired Mtdna Replication And Thus To Treat A Range Of Neurological And Neurodegenerative Disorders

Licensing agreements:

- 1. Small molecule therapies for mitochondrial disorders. Ownership transfer agreement with UCL Business.



6.1.5



Neurosciences Area

Sensory
Neurodegeneration

AWARDED HR
POSITIONS

Private competitive
programmes



Predoctoral
contracts

HR

Manager

Irigoyen Laborra, Cristina
Ruiz Ederra, Javier

Team

Postdoctoral Researcher

Acera Osa, Arantxa
Alberdi Ibarloza, Txomin
Martínez Soroa, Itziar
Muguerza Iraola, Raquel
Rodríguez Aguirreche, Iñaki

Permanent Clinical Researcher

Juaristi Eizmendi, Leire
Ruiz Miguel, Miguel
Ubeda Erviti, Marta

PhD Student

Elorza Lopez, Garbiñe
Lara López, Araceli
Mendizabal Bengoa, Amaïur
Sarasola Gastezi, Miren Nekane

PROJECTS

Active projects
Public competitive
programmes

National, 2

Autonomous, 3


Total 5

Public competitive
programme projects
awarded

Autonomous, 2

Total 2

SCIENTIFIC
OUTPUT



TRANSFER

Patent family:

1. Triazoles for the treatment of ocular diseases

HIGHLIGHTED ARTICLES

01. Lara López A, Gonzalez Imaz K, Rodríguez Hidalgo M, Sarasola Gastesi M, Escudero Arrarás L, Milla Navarro S et al. Topical Administration of Novel FKBP12 Ligand MP-004 Improves Retinal Function and Structure in Retinitis Pigmentosa Models. Invest. Ophthalmol. Vis. Sci. 2025; 66(3):56-56.

02. Millá E, Moreno Montañés J, Duch S, Lanzagorta A, Téllez J, Piá JV et al. Predictive factors for the success of the Paul glaucoma implant: a one-year multicenter prospective study. Sci Rep. 2025; 15(1):38284-38284.

03. Basasoro A, Mendicute J, Rezola M, Burgos J, Fernandez M, Esporrin Ubieto D et al. The influence of amniotic membrane proteins on corneal regeneration when delivered directly or using hydrogel platforms. Front. Med. 2025; 121498319-1498319.

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 2

Clinical research with medical devices (MDs), 1

Observational studies (with MPs and MDs), 3

Total active clinical studies 6

TRAINING



Total doctoral
theses defended

6.1.6

Neurosciences Area

Mental Health and
Psychiatric Care

HR

Managers

Gabilondo Cuéllar, Andrea

Team

Postdoctoral Researcher

Aperribai Unamuno, Leire
Hernandez Álvarez, Fabián
Loinaz Calvo, Ismael
Martínez Riera, Roser
Muela Aparicio, Alexander
Oscoz Irurozqui, Maitane
Pereda Pereda, Eva
Pérez Fernández, José Ignacio
Salaberria Irizar, Karmele
Sarrionandia Peña, Ainize

Permanent Clinical Researcher

Iruin Sanz, Álvaro
Múzquiz Jiménez, Álvaro
Plata Redondo, Raquel
Zapirain Etxebeste, Edurne

Senior Research Technician

Riera Martín, Anna
Ruiz Iriondo, María
Valencia Villareal, Macarena

PROJECTS

Active projects
Public competitive
programmes

Autonomous, 4

Total 4

Public competitive
programme projects
awarded

Autonomous, 2

Total 2

SCIENTIFIC
OUTPUT

14

Total
publications

12

Citable

42%

Q1

8%

D1

50%

Leadership

92%

Open
access

PARTICIPATION IN
CONFERENCES

33

Presentations

13

Posters

TRANSFER

Intellectual property:

1. Olímpicamente

HIGHLIGHTED ARTICLES

01.

Nunnink M, Ballester L, Vilagut G, Alayo I, Mortier P, Almenara J et al. Depression and anxiety: A 3-year follow-up study of associated risk and protective factors among university students. J Affect. Disord. 2025; 391:120058-120058.

02.

Garcia Ormaza J, Tabares JV, Ammendola E, Muela A. Mental pain and lifetime suicide attempts in early adolescence: a preliminary study. Child Adolesc. Psychiatry Ment. Health. 2025; 19(1):30-30.

03.

Oscoz Irurozqui M, Villani L, Martinelli S, Ricciardi W, Gualano MR. Trend analysis of antidepressant consumption in Italy from 2008 to 2022 in a public health perspective. Sci Rep. 2025; 15(1):12124-12124.

TRAINING

3

Total doctoral
theses defended

1

Internationally
recognised theses

6.1.7

Neurosciences Area

 Stroke

HR

Managers
De La Riva Juez, Patricia
Quiñones Gonzalez, Iliana

Team
Senior Researcher
De Arce Borda, Ana Maria
Lüttich Uroz, Alexandre
PhD Student
Jauregi Iarrañaga, Carlota
Laspiur Gandara, Raquel Sofia
Rego Garcia, Iago

Permanent Clinical Researcher
Alonso Lacabe, Maitane
Alvarez Agoues, Kattalin
Anabitarte Gonzalez, Maier
Diez Gonzalez, Noemi
Buran Sevik, Oznur
Corroza Laviñeta, Jon
Equiza Bazan, Jon
Garmendia Lopetegui, Eñaut
Gonzalez Holgado, Elena
Gonzalez Lopez, Felix
Larrea Peña, Jose Angel
Lopez De Turiso Lopez, Arantza
Marcos Osuna, Maria Macarena
Marta Enguita, Juan
Martinez Zabaleta, Maria Teresa


Senior Research Technician
Diez Zabala, Iñigo

PROJECTS

**Active projects
Public competitive
programmes**
National, 2
Autonomous, 2
Local, 2
Total 6

**Projects awarded
Public competitive
programmes**
Autonomous, 1
Total 1

SCIENTIFIC
OUTPUT



PARTICIPATION IN
CONFERENCES



HIGHLIGHTED ARTICLES

- 01.**
Renu A, de la Riva P, Delgado Mederos R, Dorado L, Fernandez Couto MD, Herrera Isasi M et al. Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial: study protocol. Stroke Vasc. Neurol. 2025;
- 02.**
de la Riva P, Rodriguez Antigüedad J, Marta Enguita J, Gomez V, Arenaza G, Gorostidi A et al. The role of endothelial dysfunction in the age-related poor prognosis of stroke patients undergoing endovascular treatment. J Stroke Cerebrovasc Dis. 2025; 34(10):108412-108412.
- 03.**
Quinones I, Gisbert Munoz S, Bermudez G, Pomposo I, Robles SG, Carreiras M et al. Transient selective aphasia in highly proficient bilinguals triggered by electrical stimulation of the left superior temporal gyrus. Acta Neurochir. 2025; 167(1):99-99.

CLINICAL TRIALS

Clinical Research
Clinical trials with medicinal products (MPs), 3
Clinical research with medical devices (MDs), 0
Observational studies (with MPs and MDs), 1
Total active clinical studies 1

TRAINING



6.1.8

Neurosciences Area

Neurogenetics, biology and RNA therapies - NeuroRNA

HR

Managers

Blazquez García, Lorea
Iruzubieta Agudo, Pablo

Team

Postdoctoral Researcher

Alonso Martinez De Marañon, Josune
Santos-García Sanz, Irene
Velasco Bilbao, Ane

Permanent Clinical Researcher

Bastida Lertxundi, Nerea
Crettaz , Julien Swen
Garces Martinez, Juan Pablo
Saez Villaverde, Raquel

PhD Student

Damborenea Moreno, Alberto
Lizartza Elustondo, Izaro
Manterola Larrañaga, María
Olaizola Barcena, Ekiñe
Pérez Fernandez, Laura
Rubio Zulaika, Ane
Sarmiento Iturbe, Fernando

Senior Research Technician

Carazo Hidalgo, María

PROJECTS

Active projects
Public competitive programmes

National, 2
Autonomous, 8

Active projects
Private competitive programmes

National, 1
Autonomous, 1


Total 12

Projects awarded
Public competitive programmes


National, 1
Autonomous, 4

Total 5

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



TRANSFER

Patent family:

1. Methods and compositions for the diagnosis and/or treatment of proteinopathies.

HIGHLIGHTED ARTICLES

01. Iruzubieta P, Verdú Díaz J, Töpf A, Luce L, Claeys KG, De Ridder W et al. Clinical and imaging spectrum of non-congenital dominant ACTN2 myopathy. J. Neurol. 2025; 272(2):150-150.
02. Chelban V, Pellerin D, Vijiaratnam N, Lee H, Goh YY, Brown L et al. Intronic FGF14 GAA repeat expansions impact progression and survival in multiple system atrophy. Brain. 2025; 148(9):3252-3265.
03. Muelas N, Iruzubieta P, Damborenea A, Perez Fernández L, Azorin I, Garcia JCJ et al. SNUPN-Related Muscular Dystrophy: Novel Phenotypic, Pathological and Functional Protein Insights. Ann. Clin. Transl. Neurol. 2025; 13(2):285-295.

TRAINING



6.2 Liver and Gastrointestinal Diseases Area

LIVER AND GASTROINTESTINAL DISEASES AREA

Gastrointestinal Diseases

Liver Diseases

Liver Immuno-Oncology

Metabolism and Cancer

Scientific objectives and progress in 2025

The following monitoring objectives were successfully achieved during 2025:

- Build on the results achieved so far in publications and research projects.
- Secure and retain postdoctoral staff as permanent and structural members of the group.
- Incorporate clinical practitioners into medical research.

Most Notable Publications in 2025

Castells A, Quintero E, Bujanda L et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. Lancet. 2025; 405(10486):1231-1239.

Bujanda L, Sánchez A, Moreira L, Prat R, Hernández Mesa G, Rodríguez Alcalde D et al. Pancreatic cancer and biliary tract tumors in individuals with lynch syndrome. Dig. Liver Dis. 2025; 57(12):2464-2469.

Olaizola I, Odriozola Gimeno M, Olaizola P, Caballero Camino FJ, Pastor Toyos N, Tena Garitaonandia M et al. New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas. J. Hepatol.

Cielica E, Laba A, Milkiewicz P, Kruk B, Kempinska Podhorodecka A, Klos P et al. The Effect of Ursodeoxycholic Acid (UDCA) on Serum Expression of miR-34a and miR-506 in Patients with Chronic Cholestatic Liver Diseases. Cells. 2025; 14(15):

Iturbe Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, Castro RE et al. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis. 2025; 400119053-119053.



6.2.1

Liver and Gastrointestinal Diseases Area

Gastrointestinal Diseases

AWARDED HR POSITIONS

Private competitive programmes



Postdoctoral contracts

HR

Manager

Bujanda Fernández de Piérola, Luis

Team

Postdoctoral Researcher

Alonso Galán, Horacio
Izquierdo Sánchez, Laura

Permanent Clinical Researcher

Barrero Iñíguez, Maialen
Etxart Lopetegui, Ane
Gil Lasa, Inés

PhD Student

Nafría Jiménez, Beatriz

Platform Manager

Hijona Muruamendaraz, Elizabeth

Laboratory Technician

Goitia Viaña, Ana

PROJECTS

Active projects
Public competitive programmes

National, 1

Autonomous, 4

Local, 1

Active projects
Private competitive programmes

National, 1

Total 7

Public competitive programme projects awarded


Autonomous, 1

Private competitive programme projects awarded

National, 1

Total 2

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



Presentations



Posters

TRANSFER

Patent family:

1. Saliva-based diagnostic test for eosinophilic oesophagitis.
2. Compositions and Methods for the Treatment of Cancer

Start-up:

1. Smart Peer Reviewers S.L.

HIGHLIGHTED ARTICLES

01. Castells A, Quintero E, Bujanda L, Castan Cameo S, Cubiella J, Diaz Tasende J et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. Lancet. 2025; 405(10486):1231-1239.
02. Bujanda L, Sánchez A, Moreira L, Prat R, Hernández Mesa G, Rodríguez Alcalde D et al. Pancreatic cancer and biliary tract tumors in individuals with lynch syndrome. Dig. Liver Dis. 2025; 57(12):2464-2469.
03. Sanchez A, Castillo Iturra J, Roos VH, Due as N, Pineda M, Moreno L et al. Gene-Specific Detection Rate of Adenomas and Advanced Adenomas in Lynch Syndrome. Gastroenterology. 2025; 169(4):663-675.

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 1
Clinical research with medical devices (MDs), 1
Observational studies (with MPs and MDs), 3

Total active clinical studies 5

TRAINING



Total doctoral theses defended



Internationally recognised theses

6.2.2

Liver and Gastrointestinal Diseases Area

Liver Diseases

AWARDED HR POSITIONS

Private competitive programmes

1

Predoctoral contracts

Public competitive programmes

1

Postdoctoral contracts

HR

Manager

Bañales Asurmendi, Jesús María

Team

Postdoctoral Researcher

Caballero Camino, Francisco Javier
Olaizola Rebé, Irene

Permanent Clinical Researcher

Aguirre Allende, Ignacio
Alustiza Echeberria, José María
Beguiristain Gómez, Adolfo
Castiella Eguzkiza, Agustín
De Juan Echavarri, María Dolores
Gallego Otaegui, Lander
Gutiérrez San Jose, Elide
Jiménez Agüero, Raúl
La Casta Muñoa, Adelaida
Pastor Bonel, Tania
Pérez Castaño, Ylenia
Ruiz Montesinos, Inmaculada
Zapata Morcillo, Eva

PhD Student

Markaide García, Enara
Pastor De los Toyos, Noelia

Platform Manager

Riaño Fernández, Ioana

Senior Research Technician

Coelho Do Val, Beatriz

PARTICIPATION IN CONFERENCES

21

Presentations

32

Posters

PROJECTS

Active projects
Public competitive programmes

National, 2

Autonomous, 6

Local, 1

Active projects
Private competitive programmes

International, 6

National, 1

Total 16

Public competitive programme projects awarded

International, 1

Autonomous, 2

Private competitive programme projects awarded

International, 1

Total 4

SCIENTIFIC OUTPUT

45

Total publications

30

Citable

83%

Q1

40%

D1

17%

Leadership

87%

Open access

HIGHLIGHTED ARTICLES

01.

Olaizola I, Odriozola Gimeno M, Olaizola P, Caballero Camino FJ, Pastor Toyos N, Tena Garitaonandia M et al. New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas. J. Hepatol.

02.

Olaizola P, Olaizola I, Fernandez de Ara M, Lapitz A, Val B, Izquierdo Sanchez L et al. Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk. Hepatology. 2025; 82(6):1461-1479

03.

Castells A, Quintero E, Bujanda L, Castan Cameo S, Cubiella J, Diaz Tasende J et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inf

TRANSFER

Patent families:

1. Combined therapeutic strategy for polycystic liver disease using new HDAC6 inhibitors derived from UDCA.
2. Polyelectrophilic metallated heterocycles derived from 2-(PYRIDIN-2-YL)IMIDAZO[1,2-A]PYRIDINE and their use as chemotherapeutic agents.
3. Inventors of the patent METHODS OF TREATING CANCER, owned by Intercept Pharmaceuticals Inc.
4. Device for cell culture.
5. Compositions and Methods for the Treatment of Cancer

Know-how licence:

1. OWL FAT - serum metabolomic fingerprint for accurate and non-invasive prediction of liver fat concentration.
2. OWL GENOMICS - serum metabolomic fingerprint for prognosis in NAFLD/NASH based on genetic polymorphism associations.

Licensing agreements:

1. OWL FAT - Joint Ownership Agreement and Exploitation Licence Agreement with ONE WAY LIVER, S.L.
2. OWL GENOMICS - Joint Ownership Agreement and Exploitation Licence Agreement with ONE WAY LIVER, S.L.
3. Development of new selective HDAC6 inhibitors derived from ursodeoxycholic acid. Preferential licence agreement with NOWTURE BIO.

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 9

Clinical research with medical devices (MDs), 0

Observational studies (with MPs and MDs), 2

Total active clinical studies 11

TRAINING

3

Total doctoral theses defended

1

Internationally recognised theses

6.2.3

Liver and Gastrointestinal Diseases Area

Liver Immuno-Oncology

AWARDED HR POSITIONS

Public competitive programmes



Internships

HR

Manager

Perugorria Montiel, Maria Jesus

Team

Postdoctoral Researcher

Agirre Lizaso, Aloña

PhD Student

Huici Izagirre, Maider
Uria Ayerbe, Ainhoa
Urretabizkaia Garmendia, Josu

PROJECTS

Active projects
Public competitive programmes

National, 2

Autonomous, 1

Active projects
Private competitive programmes

National, 1


Total 4

Private competitive programme projects awarded

National, 1

Total 1

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



Presentations



Posters

HIGHLIGHTED ARTICLES

- 01.**
Olaizola I, Odriozola Gimeno M, Olaizola P, Caballero Camino FJ, Pastor Toyos N, Tena Garitaonaindia M et al. New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas. J. Hepatol. 2025; 83(5):1077-1091.
- 02.**
Olaizola P, Olaizola I, Fernandez de Ara M, Lapitz A, Val B, Izquierdo Sanchez L et al. Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk. Hepatology. 2025; 82(6):1461-1479.
- 03.**
Cielica E, Laba A, Milkiewicz P, Kruk B, Kempinska Podhorodecka A, Klos P et al. The Effect of Ursodeoxycholic Acid (UDCA) on Serum Expression of miR-34a and miR-506 in Patients with Chronic Cholestatic Liver Diseases. Cells. 2025; 14(15):

6.2.4

Liver and Gastrointestinal Diseases Area

Metabolism and Cancer

HR

Manager

Rodrigues Vieira, Pedro Miguel

Team

Postdoctoral Researcher

Azparren Angulo, María
Lapitz Dambolenea, Ainhoa
Lasa Elozegi, Irune

PhD Student

Aranguren Esnal, Irati
De Melo Fernandes Henriques, Carolina
Iturbe Rey, Santiago

PROJECTS

Active projects
Public competitive programmes

International, 1

National, 2

Autonomous, 1

Local, 1

Active projects
Private competitive programmes

International, 1

National, 1

Total 7

Public competitive
programme projects awarded

International, 1

National, 1

Private competitive
programme projects awarded

International, 1

Total 3

SCIENTIFIC
OUTPUT

14

Total publications

8

Citable

88%

Q1

25%

D1

25%

Leadership

100%

Open access

PARTICIPATION IN
CONFERENCES

14

Presentations

16

Posters

HIGHLIGHTED ARTICLES

01.

Olaizola I, Odriozola Gimeno M, Olaizola P, Caballero Camino FJ, Pastor Toyos N, Tena Garitaonandia M et al. New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas. J. Hepatol. 2025; 83(5):1077-1091.

02.

Olaizola P, Olaizola I, Fernandez de Ara M, Lapitz A, Val B, Izquierdo Sanchez L et al. Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk. Hepatology. 2025; 82(6):1461-1479.

03.

Cielica E, Laba A, Milkiewicz P, Kruk B, Kempinska Podhorodecka A, Klos P et al. The Effect of Ursodeoxycholic Acid (UDCA) on Serum Expression of miR-34a and miR-506 in Patients with Chronic Cholestatic Liver Diseases. Cells. 2025; 14(15):

TRAINING

2

Total doctoral theses defended

1

Internationally recognised theses

6.3 Infectious Diseases Area

INFECTIOUS DISEASES AREA

Sexually Transmitted Infections

Infectious Epidemiology and Antimicrobial Resistance

Infectious Diseases and Global Health

Scientific objectives and progress in 2025

The following monitoring objectives were successfully achieved during 2025:

- Promote the translational application of research results.
- Integrate various research groups within the area.
- Explore new inter-area research lines.
- Enhance publication impact.
- Incorporate best practices aligned with RRI (Responsible Research and Innovation).

Most Notable Publications in 2025

Vidaur L, Guridi A, Leizaola O, et al. Respiratory dysbiosis as prognostic biomarker of disease severity for adults with community-acquired pneumonia requiring mechanical ventilation. *Pneumonia*. 2025; 17(1):10-10.

GIL ALONSO L. DOCUMENTO DE CONSENSO SOBRE LA PROFILAXIS POSEXPOSICIÓN OCUPACIONAL Y NO OCUPACIONAL AL VIH, VHB Y VHC EN ADULTOS Y NIÑOS. ACTUALIZACIÓN 2025. Grupo de estudio de SIDA (GeSIDA) y grupo de estudio de hepatitis víricas (GEHEP) del SEIMC, el grupo de estudio de infectología pediátrica de la Sociedad española de Pediatría y la Sociedad Española de Medicina Preventiva, Salud Pública y Gestión Sanitaria (SEMPSPGS).

Laporte Amargos J, Carmona Torre F, Huguet M, et al. Efficacy of extended infusion of (3-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial. *Clin. Microbiol. Infect.* 2025; 31(2):211-219.

Hurtado A, Ocejo M, Oporto B, et al. A One Health approach for the genomic characterization of antibiotic-resistant *Campylobacter* isolates using Nanopore whole-genome sequencing. *Front. Microbiol.* 2025; 161540210-1540210.


VERA MDM,SOTOMAYOR C,PIÑEIRO LD. Infecciones de transmisión sexual. En:Manual de Patología Infecciosa en Urgencias. España:Estratagama. 2025.



Infectious Diseases Area

6.3.1 Sexually Transmitted Infections

SCIENTIFIC OUTPUT



HR

Manager
Piñeiro Vázquez, Luis Darío

Team
Permanent Clinical Researcher
Arrastia Erviti, Maitane
Cuñado Eizaguirre, Amaia
Gil Alonso, Leire
Idigoras Viedma, Pedro
Lasa Alvarado, Izaskun

HIGHLIGHTED ARTICLES

- 01.**
GIL ALONSO L. DOCUMENTO DE CONSENSO SOBRE LA PROFILAXIS POSEXPOSICIÓN OCUPACIONAL Y NO OCUPACIONAL AL VIH, VHB Y VHC EN ADULTOS Y NIÑOS. ACTUALIZACIÓN 2025. Grupo de estudio de SIDA (GeSIDA) y grupo de estudio de hepatitis víricas (GEHEP) de la sociedad española de enfermedades infecciosas y microbiología clínica (SEIMC), el grupo de estudio de infectología pediátrica de la Sociedad española de Pediatría y la Sociedad Española de Medicina Preventiva, Salud Pública y Gestión Sanitaria (SEMPSPGS).
- 02.**
VERA MDM,SOTOMAYOR C,PIÑEIRO LD. Infecciones de transmisión sexual. En:Manual de Patología Infecciosa en Urgencias. España:Estratagema. 2025.
- 03.**
Pineiro L, Idigoras P, Manzanal A, Ansa I, Vicente D. Mycoplasma penetrans urethritis in men. A case-control study. Front. Microbiol. 2025; 161565685-1565685.

PROJECTS

Active projects
Public competitive programmes
Autonomous, 1
Total 1

PARTICIPATION IN CONFERENCES



6.3.2

Infectious Diseases Area

Infectious Epidemiology and Antimicrobial Resistance

HR

Manager

Marimón Ortiz de Zarate, José María

Postdoctoral Researcher

Alkorta Gurrutxaga, Mirian
Alonso Asencor, Marta
Aranzamendi Zaldumbide, Maitane
Montes Ros, Milagrosa
Vicente Anza, Diego
Vidaur Tello, Loreto

Permanent Clinical Researcher

Vallejo Recuna, Pedro

PhD Student

Rekalde Hernando, Maite Elisa

PROJECTS

Active projects
Public competitive programmes

European, 3


Total 3

Projects awarded
Public competitive programmes

European, 1

Total 1

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



TRANSFER

Intellectual property:

1. Streptococcus pneumoniae serotyping kit.

Licensing agreement:

1. Co-ownership and commercial exploitation licence agreement with OPERON S.L.

HIGHLIGHTED ARTICLES

01. Vidaur L, Guridi A, Leizaola O, Marin J, Rello J, Sarasqueta C et al. Respiratory dysbiosis as prognostic biomarker of disease severity for adults with community-acquired pneumonia requiring mechanical ventilation. Pneumonia. 2025; 17(1):10-10.
02. Hurtado A, Ocejó M, Oporto B, Lavin JL, Rodríguez R, Marcos MA et al. A One Health approach for the genomic characterization of antibiotic-resistant Campylobacter isolates using Nanopore whole-genome sequencing. Front. Microbiol. 2025; 16:1540210-1540210.
03. Vallejo P, Moura A, López Olaizola M, Leclercq A, Vicente D, Lecuit M et al. Improved detection of Listeria monocytogenes outbreaks using whole genome sequencing, Gipuzkoa, Northern Spain, 2010 to 2022. BMC Microbiol. 2025; 26(1):41-41.

TRAINING



6.3.3

Infectious Diseases Area

Infectious Diseases and
Global Health

HR

Manager

Carmona de la Torre, Francisco de Asís
Ibarguren Pinilla, Maialen

Team

Postdoctoral Researcher

Balerdi Sarasola, Leire

Permanent Clinical Researcher

Álvarez Rodríguez, Ignacio
Azkune Galparsoro, Harkaitz
Bayona Carlos, Ana
Bustinduy Odriozola, María Jesús
Camino Ortiz de Barrón, Xabier
Gil Alonso, Leire
Goenaga Sánchez, Miguel Angel
Iribarren Loyarte ,Jose Antonio
Lopez Olaizola, Maddi
Kortajarena Urkola, Xabier

Senior Research Technician

Nevado Pavon, Claudia


PROJECTS

Active projects
Public competitive
programmes

Local, 1

Total 1

SCIENTIFIC
OUTPUT



HIGHLIGHTED ARTICLES

01. Laporte Amargos J, Carmona Torre F, Huguet M, Puerta Alcalde P, Rigo Bonnin R, Uildemolins M et al. Efficacy of extended infusion of (3-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial. Clin. Microbiol. Infect. 2025; 31(2):211-219.
02. Berenguer J, Fanciulli C, Arcos MM, Vivancos MJ, Domingo P, Hernando A et al. Trends in HCV Infection Prevalence Among People with HIV in Spain Over Two Decades (2002-2023). Clin Infect Dis. 2025;
03. Cuervo G, Hernandez Meneses M, de Alarcon A, Luque Marquez R, Alonso Socas MM, Lopez Lirola A et al. Oral vs. Outpatient Parenteral Antimicrobial Treatment for Infective Endocarditis: Study Protocol for the Spanish OraPAT-IE GAMES Trial. Infect. Dis. Ther. 2025; 14(3):643-655.

CLINICAL TRIALS

Clinical Research

- Clinical trials with medicinal products (MPs), 5
- Clinical research with medical devices (MDs), 0
- Observational studies (with MPs and MDs), 1

Total active clinical studies 6

6.4 Oncology Area

ONCOLOGY AREA

Breast Cancer

Cellular
Oncology

Molecular
Oncology

Brain Tumors

Scientific objectives and progress in 2025

The following monitoring objectives were successfully achieved during 2025:

- At least 1 project submitted to funding agencies with team members from 2 or more groups within the area.
- At least 1 new research line developed in collaboration between 2 or more groups within the area.
- 2 or more publications signed by members of 2 or more groups in the area.
- 1 doctoral thesis co-directed by members of 2 or more groups within or outside the area.
- 2 or more joint seminars involving members of 2 or more groups within the area.
- 2 or more projects submitted to funding agencies involving another entity and/or industry partner.

Most Notable Publications in 2025

Manzano S, Caffarel MM. Cytokine-centered strategies to boost cancer immunotherapy. Mol. Oncol. 2025; 19(3):579-583.

Tivanello RG, Armesto M, Ariseto AP, Lawrie CH. MicroRNA Expression During Long-Term Treatment With 3-MCPD and Glycidol In Vitro. J. Appl. Toxicol. 2025;

Marcos Perez D, Hernandez Vicente A, Cruces Salguero S, Landa J, Bonvini M, Vicente Rodríguez G et al. Resistance Exercise Intervention Restores Functional Capacity and Improves Frailty Biomarkers in Centenarians. J. Cachexia Sarcopenia Muscle. 2025; 16(5):

Aliee H, Bejarano Bosque L, Castells Graells R, Caswell D, Friedrich MJ, Gurjao C et al. THE 2025 generation. Nat. Cancer. 2025; 6(12):1930-1934.

López Velazco JI, Manzano S, Elorriaga K, Otaño M, Lahuerta A, Álvarez L et al. Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response. Transl. Oncol. 2025; 57102407-102407.



6.4.1

Oncology Area

Breast Cancer

AWARDED HR POSITIONS

Public competitive programmes

2

Predoctoral contracts

1

Postdoctoral contracts

2

Scholarship

Competitivos Privados

3

Predoctoral contracts

1

Scholarship

HR

Managers

Álvarez López, Isabel Manuela
Muñoz Caffarel, María
Urruticoechea Ribate, Ander

Team

Senior Researcher

Urruticoechea Ribate, Ander
Garmendia Iturbe, Irati

Postdoctoral Researcher

Arrieta Etxeberria, Haritz
Azcoaga Azcoaga, Peio
Duch Gili, Paula
Garzon Tituaña, Marcela
Gonzalez Perez, Maria Feliciano
Manzano Figueroa, Sara

Permanent Clinical Researcher

Álvarez Cuesta, Luis
Ancizar Lizarraga, Nerea
Fernández Calleja, Marta
Guimón Olaizola, Elena
Lahuerta Martinez, Ainara
Otaño Ariño, Maria
Paisán Ruiz, Ana
Rezola Bajineta, Marta
Urraca de la Serna, José María

PhD Student

Alvarez Huesa, Uxue
Miner Irazu, June
Petit de Prado, Paloma
Romo Valera, Ainhoa
Sánchez Castro Adrián

Laboratory Technician

Telletxea Garmendia, Zuhara

PROJECTS

Active projects
Public competitive programmes

International, 1
National, 8
Autonomous, 3
Local, 1

Active projects
Private competitive programmes

National, 6
Total 19

Public competitive
programme projects awarded

International, 1
National, 2

Active projects
Private competitive programmes

National, 1
Total 4

SCIENTIFIC OUTPUT

23

Total publications

18

Citable

50%

Q1

22%

D1

11%

Leadership

94%

Open access

1

Clinical practice guidelines

PARTICIPATION IN CONFERENCES

15

Presentations

24

Posters

TRANSFER

Patent families:

1. Alginate-based hydrogel compositions and their uses.

HIGHLIGHTED ARTICLES

01.

Manzano S, Caffarel MM. Cytokine-centered strategies to boost cancer immunotherapy. Mol. Oncol. 2025; 19(3):579-583.

02.

López Velazco JI, Manzano S, Elorriaga K, Otaño M, Lahuerta A, Álvarez L et al. Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2-breast cancer uncovers biomarkers of tumour response. Transl. Oncol. 2025; 57102407-102407.

03.

Schouten A, Hiensch AE, Frederix GWJ, Monninkhof EM, Schmidt ME, Clauss D et al. Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial. J. Clin. Oncol. 2025; 43(11):1325-1336.

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 37

Clinical research with medical devices (MDs), 0

Observational studies (with MPs and MDs), 3

Total active clinical studies 40

TRAINING

1

Total doctoral theses defended

6.4.2

Oncology Area

Cellular
Oncology

AWARDED HR
POSITIONS

Public competitive
programmes



Juan de la
Cierva contract



Sara Borrell
contract

HR

Manager

Matheu Fernández, Ander

Team

Senior Researcher

Carrasco García, Estefanía
Moncho Amor, Verónica
Samprón Lebed, Nicolas

Postdoctoral Researcher

Artetxe Zurutuza, Aizpea
Cruces Salguero, Sara
Iturrioz Rodríguez, Nerea
Landa Medrano, Jon
Marcos Pérez, Diego

Permanent Clinical Researcher

Arévalo Lobera, Sara
Moreno Valladares, Manuel
Ruiz Díaz, Irune

PhD Student

Aguirre Zuazo, Itxaso
Bonvini, Michelle
Egaña Otaño, Larraitx
Elizazu Pérez, Joseba
Ortiz de Urbina Ugarte, David Ignacio
Otaegi Ugartemendia, Maddalen
Villanua Bernues, Jorge Alberto

Laboratory Technician

Veragara Arce, Jhonatan Andrés

PROJECTS

Active projects
Public competitive
programmes

National, 5

Autonomous, 6

Active projects
Private competitive
programmes

Autonomous, 1

Total 12


Public competitive
programme projects
awarded

National, 2

Autonomous, 4

Total 7

SCIENTIFIC
OUTPUT



PARTICIPATION IN
CONFERENCES



Presentations

TRANSFER

Patent families:

1. Identification of molecular patterns for diagnosis and stratification of frail individuals.
2. Functional capacity analysis device.
3. HISTONE DEACETYLASE DERIVATIVES for the treatment of cancer.

Licensing agreement:

1. Functional capacity analysis device, licensed to BIOLAN S.L.

Intellectual property:

1. Resilience Index for Assessing Aging

HIGHLIGHTED ARTICLES

01. Marcos Perez D, Hernandez Vicente A, Cruces Salguero S, Landa J, Bonvini M, Vicente Rodríguez G et al. Resistance Exercise Intervention Restores Functional Capacity and Improves Frailty Biomarkers in Centenarians. J. Cachexia Sarcopenia Muscle. 2025; 16(5):
02. Cruces Salguero S, Sol J, Larrañaga I, Pamplona R, Mar J, Jove M et al. Analysis of sex-specific disease patterns associated with human lifespan. GeroScience. 2025; 47(3):2639-2654.
03. Artetxe Zurutuza A, Iturrioz Rodriguez N, Elizazu J, Toledano Pinedo M, Porro Pérez A, De Goni I et al. Generation and validation of a novel multitarget small molecule in glioblastoma. Cell Death Dis. 2025; 16(1):250-250.

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 1

Clinical research with medical devices (MDs), 1

Observational studies (with MPs and MDs), 0

Total active clinical studies 2

TRAINING



Total doctoral
theses defended

6.4.3

Oncology Area

Molecular
Oncology

AWARDED HR
POSITIONS

Public competitive
programmes



Predoctoral
contracts

HR

Manager

Lawrie, Charles

Team

Senior Researcher

Basterretxea Badiola, Laura
Ceberio Echechipia, Izaskun
Solé Cañadas, Carla

Postdoctoral Researcher

Armesto Álvarez, María Consuelo
Bourantas, Dimitrios
Konstantinov, Apostol Apostolov
De la Encarnación Bermudez, Cristina
Martínez De Arbulo Echebarria Miguel
Martínez Riaño, Ana
Marquez Lopez, Maitane
Panizo Santos, Carlos Manuel

Permanent Clinical Researcher

Araiz Ramírez, María
Bernal Simón, Iraide

PhD Student

Beltran Sánchez, Claudia
Gurrutxaga Navas, June

Senior Research Technician

Arestin Muruzabal, María

Laboratory Technician

Arocena Bertiz, Leire
Carretero Dominguez, Francisco Jose
Centeno Barrio, Diego

PROJECTS

Active projects
Public competitive
programmes

International, 1
National, 2
Autonomous, 5
Local, 1

Active projects
Private competitive
programmes

National, 2
Autonomous, 1


Total 12

Public competitive
programme projects
awarded

National, 2
Autonomous, 1
Local, 1

Total 4

SCIENTIFIC
OUTPUT



PARTICIPATION IN
CONFERENCES



Presentations



Posters

TRANSFER

Patent families:

1. Modular multiwell plates for cell culture,
optimised for Raman spectroscopy imaging.

HIGHLIGHTED ARTICLES

01. Tivanello RG, Armesto M, Ariseto AP, Lawrie CH. MicroRNA Expression During Long-Term Treatment With 3-MCPD and Glycidol In Vitro. J. Appl. Toxicol. 2025;

02. Montes MR, Suarez B, Solano Iturri JD, Lecumberri D, Iturregui AM, Lawrie CH et al. Fibroblast Activation Protein Alpha (FAP) Expression Is Associated with Disease Recurrence and Poor Response to Tyrosine Kinase Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. Int. J. Mol. Sci. 2025; 26(22):

03. Gutierrez A, Zeberio I, Penalver FJ, Martinez Barranco P, Perez S, Morillo D et al. Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO. Blood Adv. 2025; 9(19):4924-4935.

CLINICAL TRIALS

Clinical Research

Clinical trials with
medicinal products
(MPs), 9

Clinical research
with medical devices
(MDs), 0

Observational studies
(with MPs and MDs), 2

Total active clinical
studies 11

TRAINING



Total doctoral
theses defended



Internationally
recognised theses

Oncology Area

6.4.3 Brain Tumors

AWARDED HR POSITIONS

Public competitive programmes



Predoctoral contracts



Postdoctoral contracts

SCIENTIFIC OUTPUT

HR

Manager

Bejarano Bosque, Leire

HIGHLIGHTED ARTICLES

01.

Aliee H, Bejarano Bosque L, Castells Graells R, Caswell D, Friedrich MJ, Gurjao C et al. THE 2025 generation. Nat. Cancer. 2025; 6(12):1930-1934.

PARTICIPATION IN CONFERENCES



Presentations



Total publications



Citable



Q1



D1



Leadership

PROJECTS

Active projects
Public competitive programmes

National, 1

Total 1

Public competitive programme projects awarded

International, 1

National, 1

Total 2



6.5 Systemic Diseases Area

SYSTEMIC DISEASES AREA

Heart Diseases

Obstetrics and Gynaecology

Otolaryngology and Head and Neck Surgery

Paediatrics

Respiratory and Pleural Pathology

Scientific objectives and progress in 2025

The following monitoring objectives were successfully achieved during 2024:

- Promote the translational application of research results.
- Incorporate new research groups into the area.
- Integrate various research groups within the area.
- Explore new inter-area research lines.
- Foster collaboration with the R&D&I ecosystem and the business network of the Basque Autonomous Community.
- Incorporate best practices aligned with RRI (Responsible Research and Innovation).

Most Notable Publications in 2025

Daou B, Prato M, Alonso Martin S, Alegret N. Carbon Nanotube Hydrogels Reveal Threshold-Dependent Regulation of Neuroblastoma Cell Growth and Maturation by Mechanical and Chemical Factors. *Small Sci.* 2025; 5(11):2500401-2500401.

Diez Itza I. Urinary incontinence during pregnancy and in the postpartum period. *Nat. Rev. Urol.* 2025;

Lechien JR, Hamdan AL, Maniaci A, Mayo Yanez M, Cammaroto G, Kan K et al. Gender-Related Discriminations in European Otolaryngology-Head and Neck Surgery: European Report. *Surg. Innov.* 2025; 32(6):551-561.

Abdel Aziz MI, Hashimoto S, Neerincx AH, Haarman EG, Cecil A, Lintelmann J et al. Metabotypes are linked to uncontrolled childhood asthma, gut microbiota, and systemic inflammation. *J Allergy Clin Immunol.* 2025; 156(2):339-351.

Garcia Zamalloa A, Arnay R, Castilla Rodriguez I, Mar J, Gonzalez Cava JM, Ibarrondo O et al. Machine learning for predicting the diagnosis of tuberculous versus malignant pleural effusion: External validation and accuracy in two different settings. *PLoS One.* 2025; 20(9):



6.5.1

Systemic Diseases Area

Heart Diseases

AWARDED HR POSITIONS

Public competitive programmes

2

Predoctoral contracts

HR

Manager

Alegret Ramon, Nuriar
Arana Achaga, Xabier

Team

Permanent Clinical Researcher

Alarcon Duque, Jose Antonio
Goena Vives, María Cristina
Perez Martinez, Clara Isabel
Solla Ruiz, Itziar
Villanueva Benito, Iñaki

PhD Researcher

Miner Oruesagasti, Ander

PROJECTS

Active projects
Public competitive programmes

International, 1

National, 1

Autonomous, 2

Active projects
Private competitive programmes

National, 1

Total 5

Projects awarded
Public competitive programmes

European, 1

Autonomous, 1

Total 3

SCIENTIFIC OUTPUT

11

Total publications

9

Citable

56%

Q1

11%

D1

22%

Leadership

56%

Open access

PARTICIPATION IN CONFERENCES

3

Presentations

HIGHLIGHTED ARTICLES

01.

Daou B, Prato M, Alonso Martin S, Alegret N. Carbon Nanotube Hydrogels Reveal Threshold-Dependent Regulation of Neuroblastoma Cell Growth and Maturation by Mechanical and Chemical Factors. Small Sci. 2025; 5(11):2500401-2500401.

02.

Marta Enguita J, De La Riva P, De Arce A, Diez N, Gonzalez F, Equiza J et al. IMPACT OF ORGANIZATIONAL CHANGES IN CARDIOLOGICAL EVALUATION ON THE MANAGEMENT OF ISCHEMIC STROKE PATIENTS IN A STROKE UNIT: A COST-EFFECTIVENESS AND OUTCOME IMPROVEMENT ANALYSIS. Int. J. Stroke. 2025; 2094-94.

03.

Ahmed A, Alegret N, Almeida B, Alvarez Puebla R, Andrews AM, Ballerini L et al. Interfacing with the Brain: How Nanotechnology Can Contribute. ACS Nano. 2025; 19(11):10630-10717.

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 1

Clinical research with medical devices (MDs), 2

Observational studies (with MPs and MDs), 2

Total active clinical studies 5

6.5.2

Systemic Diseases Area

Obstetrics
and Gynaecology

HR

Manager

Díez Itza, Irene

Team

Senior Researcher

Jaunarena Marín, Ibon

Postdoctoral Researcher


Arrue Gabilondo, Miren
Belar Ortega, María Joséfa
Del Valle Peña, David

Permanent Clinical Researcher


Gorostidi Pulgar, Mikel
Lekuona Artola, María Aranzazu



SCIENTIFIC
OUTPUT



PARTICIPATION IN
CONFERENCES



TRANSFER

Patent families:

1. Method and device for detecting hypoxia.

Licensing agreements:

1. Method and device for assessing hypoxia, licensed to the institute's spin-off OPTEC4LIFE S.L.

Spin Off:

1. OPTEC4LIFE S.L.

HIGHLIGHTED ARTICLES

01.
Diez Itza I. Urinary incontinence during pregnancy and in the postpartum period. Nat. Rev. Urol. 2025;
02.
Gorostidi M, Ángeles M, Gil Ibáñez B, Lekuona A, Martinez A, Zapardiel I. Surgical Staging in Locally Advanced Cervical Cancer: Precision, Risks, and the 'Helmet' Analogy. Cancers. 2025; 17(21):
03.
Diez itza I, Arrue M, Aguinaga M, Goyeneche L, Nicieza M, Sarasqueta C. Spanish validation of the German pelvic floor questionnaire for pregnant and postpartum women. Int. J. Gynecol. Obstet. 2025;

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 0

Clinical research with medical devices (MDs), 2

Observational studies (with MPs and MDs), 0

Total active clinical studies 2

6.5.3

Systemic Diseases Area

Otolaryngology and Head and Neck Surgery

HR

Manager

Altuna Mariezcurrena, Xabier

Team

Postdoctoral Researcher

Chiesa Estomba, Carlos Miguel
Soriano Reixach, María Montserrat
Rey Martínez, Jorge

Permanent Clinical Researcher

Garcia Iza, Leire

PROJECTS

Active projects
Public competitive programmes

Autonomous, 1

Local, 1

Total 2

Public competitive programme projects awarded

Autonomous, 1

Total 1



SCIENTIFIC OUTPUT

37

Total publications

28

Citable

57%

Q1

7%

D1

32%

Leadership

61%

Open access

PARTICIPATION IN CONFERENCES

2

Presentations

TRANSFER

Patent families:

1. Development of cartilage grafts and tympanic membrane grafts using 3D bioprinting

HIGHLIGHTED ARTICLES

01.

Lechien JR, Hamdan AL, Maniaci A, Mayo Yanez M, Cammaroto G, Kan K et al. Gender-Related Discriminations in European Otolaryngology-Head and Neck Surgery: European Report. Surg. Innov. 2025; 32(6):551-561.

02.

Arndt S, Deguine O, Nevoux J, Sánchez S, Topçuoğlu MSY, D'hondt C et al. Long-term outcomes of tympanoplasty with persistent air-bone gap in adults with chronic otitis media: hearing, health care utilization and quality of life. Eur Arch Otorhinolaryngol. 2025; 282(10):5049-5059

03.

Chiesa Estomba CM, Rodriguez Urzay A, Landa Garmendia M, Larruscain Sarasola E, Gonzalez Garcia JA, Sistiaga Suarez JA et al. Malignant Salivary Gland Tumors in a Tertiary University Hospital in Northern Spain. J. Clin. Med. 2025; 14(1):

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 0

Clinical research with medical devices (MDs), 0

Observational studies (with MPs and MDs), 1

Total active clinical studies 1

TRAINING

2

Total doctoral theses defended

6.5.4

Systemic Diseases Area

Paediatrics

HR

Manager

Martí Carrera, Itxaso

Team

Postdoctoral Researcher

Apilanez Urkiola, Miren Alicia
Corcuera Elosegui, Paula
Gorrotxategi Gorrotxategi, Pedro
Korta Murua, Jose Javier
Larrea Tamayo, Elene
Luengo Etxebeste, Aitziber
Muga Zuriarrain, Oihana
Rezola Arcelus, Erika
Sardon Prado, Olaia

Permanent Clinical Researcher

Calvo Monge, Cristina
Camara Otegui, Amaia
De La Cuevas Teran, Maria Isabel
García Abos, Miriam
García de Andoin Barandiaran, Nagore
Juaristi Irureta, Saioa
Rocandio Cilveti, Beatriz
Satrústegi Aritziturri, Miren
Serrano Pejenaute, Idoia
Tarabini-Castellani Ciorcia, Beatriz Maria
Uriz Monaut, Jose Javier

Senior Research Technician

Aizpurua Olano, Maria Mercedes
Balza Lizarza, Amaia
Calzada Pacheco, Raquel
Da-Riva Muñoz, Teresa
Lopetegui Galdos, Ainara
Dominguez Garcia, Josune
Rekarte Cowie, Iona
Turrillas Isasi, Haizea
Urgel Muñoz, Paola Pilar

PROJECTS

Active projects
Public competitive programmes

National, 2

Autonomous, 5

Local, 3

Active projects
Private competitive programmes

Autonomous, 4

Total 14


Public competitive
programme projects awarded

Autonomous, 2

Local, 2

Total 4

SCIENTIFIC
OUTPUT



PARTICIPATION IN
CONFERENCES



HIGHLIGHTED ARTICLES

01. Abdel Aziz MI, Hashimoto S, Neerincx AH, Haarman EG, Cecil A, Lintelmann J et al. Metabotypes are linked to uncontrolled childhood asthma, gut microbiota, and systemic inflammation. J Allergy Clin Immunol. 2025; 156(2):339-351.
02. Andina Martínez D, Barrueco Ramos C, Escalada Pellitero S, Ranera Málaga A, Guerra Díez JL, Gimeno Hernández Garza V et al. Impacto desigual de la inmunización frente al virus respiratorio sincitial en los pacientes atendidos en los servicios de urgencias pediátricos españoles. Emergencias. 2025; 37(5):360-366.
03. Salazar Pérez F, Sanz Santiago V, de Mir Messa I, Sardón Prado O, Rezola Arcelus E, Corcuera Elosegui P et al. Cardiorespiratory fitness in patients with post-infectious bronchiolitis obliterans: a cross-sectional study. ERJ Open Res. 2025; 11(6):

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 2

Clinical research with medical devices (MDs), 0

Observational studies (with MPs and MDs), 2

Total active clinical studies 4

6.5.5

Systemic Diseases Area

Respiratory and Pleural Pathology

HR

Manager

García-Zamalloa Zamalloa, Alberto
Salegi Etxebeste, Iñaki

Team


PhD Student

Aguinagalde Valiente, Borja


Permanent Clinical Researcher

Royo Guitierrez, Iñaki
Gil Rodríguez, Eva Lorea
Gómez Domínguez, Celia Fátima
Inchausti Iguñiz, Marta
Juaristi Abaunz, María Aranzazu
Labeguerie Arenaza, Beñat
Lopez Sanz, Iker Javier
Miguel Arce, Juan Antonio
Rezola Carasusan, Alejandro
Rivas Guerrero, Agustina
Sayago Reza, Itxaso
Segues Merino, Nerea
Zabaleta Jimenez, Jon
Zufiaurre Echeverria, Ane

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



TRANSFER

Patent families:

1. Medical device that enables the collection of postmortem lung biopsies

Intellectual property:

1. PLEURA APP

HIGHLIGHTED ARTICLES

01. Garcia Zamalloa A, Arnay R, Castilla Rodriguez I, Mar J, Gonzalez Cava JM, Ibarrondo O et al. Machine learning for predicting the diagnosis of tuberculous versus malignant pleural effusion: External validation and accuracy in two different settings. PLoS One. 2025; 20(9):
02. Lopez I, Aguinagalde B, Ferrer Bonsoms JA, Sanchez L, Ascanio F, Sesma J et al. Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort. J. Clin. Med. 2025; 14(7):
03. Aguinagalde B, Ferrer Bonsoms JA, López I, Lizarbe JA, Fernandez Monge A, Mainer M et al. Recurrence Pattern of Left Upper Lobectomies and Trisegmentectomies: Systematic Review and Meta-Analysis. J. Clin. Med. 2025; 14(12):

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 1

Clinical research with medical devices (MDs), 0

Observational studies (with MPs and MDs), 4

Total active clinical studies 5

TRAINING



6.6 Epidemiology, Public Health and Primary Care Area

Epidemiology, Public Health and Primary Care Area

- Primary Care
- Public Health and Environmental Epidemiology
- Epidemiology of Chronic and Communicable Diseases
- Financial Evaluation of Chronic Diseases

Scientific objectives and progress in 2025

The following monitoring objectives were successfully achieved during 2025:

- Integration of the various research groups within the area being coordinated.
- Promotion of research lines and intra-area collaboration.
- Development of new research lines in collaboration between 2 or more groups in the area.
- Production of research results involving members of 2 or more groups in the area.
- Promotion of research careers within the area.

Most Notable Publications in 2025

Huerta JM, Colorado Yohar SM, Andreu Reinón ME, Mokoroa O, Tainta M, Guevara M et al. Addressing common biases in the evaluation of lifetime alcohol consumption patterns and dementia risk: the EPIC-Spain dementia cohort. *Front Nutr.* 2025; 121671047-1671047.

Ibarluzea J, Subiza Pérez M, Arregi A, Otamendi M, Luque Garcia L, Irizar A et al. Are Fluoride Levels During Prenatal Development Associated with Internalizing and Externalizing Problems in Late Childhood?. *Expo. Health.* 2025; 17(6):1357-1369.

Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C et al. IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease. *Value Health.* 2025; 28(4):497-510.

Tainta M, Ecay Torres M, Barandiaran M, Estanga A, López C, Altuna M et al. CITA GO-ON study. A community based multidomain lifestyle intervention to prevent cognitive decline. Protocol design and recruitment process. *Front. Aging Neurosci.* 2025; 171539711-1539711.

Castells A, Quintero E, Bujanda L, Castan Cameo S, Cubiella J, Diaz Tasende J et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. *Lancet.* 2025; 405(10486):1231-1239.



Epidemiology, Public Health and Primary Care Area

6.6.1 Primary Care

AWARDED HR POSITIONS

Public competitive programmes



Release of Researchers

HR

Manager

Vergara Micheltorena, Itziar
Vrotsou, Kalliopi

Team

Ad Honorem

Rotaechel del Campo, Rafael

Postdoctoral Researcher

Ettxeberria Agirre, Miren Arritokieta
Gutiérrez Stampa, María Angeles

Permanent Clinical Researcher

Antón Rodrigo, Iván
Apalategi Gómez, Uxune
Barral Juez, losu
Del Campo Peña, Emma
Díez Ruiz, Ana Isabel
Gamboa Moreno, Estíbaliz
Garaikoetxea Iturriria, Ana Isabel
González Miguel, Raquel
Güell Pelayo, Carolina
Sanchez Sanchez, Clara

Supporting Researcher

Mateo Abad, Maider

Senior Research Technician

Alonso Sampedro, Irene
Vaquez Polo, Maialen

PROJECTS

Active projects
Public competitive programmes

National, 6

Autonomous, 5

Total 11


Public competitive programme projects awarded

International, 1

Local, 2

Total 3

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



Presentations



Posters

TRANSFER

Patent families:

- 1. Device for assessing functional capacity.
- 2. Identification of molecular patterns for diagnosis and stratification of frail individuals.

Licensing agreement:

- 1. Device for assessing functional capacity. Licensed to BIOLAN S.L.

HIGHLIGHTED ARTICLES

- 01. Tainta M, Ecay Torres M, Barandiaran M, Estanga A, López C, Altuna M et al. CITA GO-ON study. A community based multidomain lifestyle intervention to prevent cognitive decline. Protocol design and recruitment process. Front. Aging Neurosci. 2025; 171539711-1539711.
- 02. Castells A, Quintero E, Bujanda L, Castan Cameo S, Cubiella J, Diaz Tasende J et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. Lancet. 2025; 405(10486):1231-1239.
- 03. CAMPO R, BOF, FLF. Trayectorias y experiencias de las personas con multimorbilidad en el Servicio Nacional de Salud 2012-2022 (Proyecto LOXO-MULTIPAP): un estudio de métodos mixtos (oral). REVISTA CLINICA DE MEDICINA DE FAMILIA. 2025;

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), 1

Clinical research with medical devices (MDs), 0

Observational studies (with MPs and MDs), 1

Total active clinical studies 1

TRAINING



Total doctoral theses defended

6.6.2

Epidemiology, Public Health and Primary Care Area

Public Health and Environmental Epidemiology

HR

Manager

Ibarluzea Maurolagoitia, Jesús María
Lertxundi Manterola, Aitana

Team

Ad Honorem

Santa Marína Rodríguez, Loreto

Postdoctoral Researcher

Álvarez Uriarte, Jon Iñaki
Andiarena Villaverde, Ainara
Arranz Freijo, Enrique
Arregi Otxotorena, Ane
Azurmendi Imaz, Aitziber
Babarro Vélez, Izaro
Barreto Zarza, Florencia Belén
Barroeta Legarreta, Ziortza
Etxebarria Foronda, Iñigo
Fano Ardanaz, Eduardo
Ferro Uriguen, Alexander
Irizar Loibide, Amaia
Jimeno Romero, Alba
Lertxundi Iribar, Nerea
Macia Guerrero, Patricia
Sánchez de Miguel, Manuel Norberto
Subiza Pérez, Mikel
Vegas Moreno, Oscar
Zubero Oleagoitia, Miren Begoña

Permanent Clinical Researcher

Acha Morcillo, Joana
Urbieta Macazaga, Nerea

PhD Student

Ayerdi Barandiaran, Mikel
Luque García, Leire
Martínez López De Dicastillo, María Dolores
San Román Martínez, Ane
Zabaleta Camino, Carlos

Senior Research Technician

Bereziartua Aranzabal, Ainhoa
Otamendi Garitano, Maialen

PROJECTS

Active projects
Public competitive programmes

International, 1
National, 3
Autonomous, 3
Local, 1

Active projects
Private competitive programmes

National, 1
Total 9


Public competitive programme projects awarded

International, 2
Autonomous, 1

Private competitive programme projects awarded

Autonomous, 1
Total 4

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



HIGHLIGHTED ARTICLES

01. Ibarluzea J, Subiza Pérez M, Arregi A, Otamendi M, Luque Garcia L, Irizar A et al. Are Fluoride Levels During Prenatal Development Associated with Internalizing and Externalizing Problems in Late Childhood?. Expo. Health. 2025; 17(6):1357-1369.
02. Subiza Pérez M, García Baquero G, Rebagliato M, Estarlich M, Guxens M, Vrijheid M et al. Residential greenness and children working memory. An EU Child Cohort Network consortium study. Environ. Res. 2025; 271121016-121016.
03. M, Poppe KG, Warringa L, Verdonk K et al. Association of gestational thyroid function and thyroid autoimmunity with gestational diabetes: a systematic review and individual participant meta-analysis. Lancet Diabetes Endocrinol. 2025; 13(8):651-661.

TRAINING



6.6.3

Epidemiology, Public Health and Primary Care Area

Epidemiology of Chronic and Communicable Diseases

HR

Group lead researcher
Jiménez Zabala, Ana

Team

Ad Honorem

Amiano Etxezarreta, Pilar
Sancho Martínez, Rosa María

Postdoctoral Researcher

Abilleira Cillero, Eunate
Imaz Goienetxea, Liher
Sarasqueta Eizaguirre, Cristina

Permanent Clinical Researcher

Aginagalde Llorente, Adrian Hugo

Senior Research Technician

Aizpurua Atxega, Amaia
Dorronsoro Erauskin, Ane
Mokoroa Carollo, Olatz

Research Technician

Alvarez Guerrico, Lorea
Gil Majuelo, Leire
López de Munain Marqués, Arantza

PROJECTS


Active projects
Public competitive
programmes

National, 2

Autonomous, 1

Total 3

SCIENTIFIC
OUTPUT



PARTICIPATION IN
CONFERENCES



HIGHLIGHTED ARTICLES

01. Huerta JM, Colorado Yohar SM, Andreu Reinón ME, Mokoroa O, Tainta M, Guevara M et al. Addressing common biases in the evaluation of lifetime alcohol consumption patterns and dementia risk: the EPIC-Spain dementia cohort. Front Nutr. 2025; 121671047-1671047.
02. Hernández A, Camps Vilaró A, Polo Alonso S, Subirana I, Ramos R, de Cid R et al. Cohort profile: the CORDELIA study (Collaborative cOHORTs Reassembled Data to study mEchanisms and Longterm Incidence of chronic diseAses). Eur. J. Epidemiol. 2025; 40(5):581
03. Barranco M, Alcala Santiago A, Galvez Navas JM, Huerta JM, Amiano P et al. Nutritional profile of the diet according to circadian clock genes in the European Prospective Investigation into Cancer and Nutrition (EPIC) chronodiet study. Clin Nutr. 2025; 49165-177.

TRAINING



6.6.4

Epidemiology, Public Health and Primary Care Area

Financial Evaluation of Chronic Diseases

HR

Group lead researcher
Merino Hernández, María Luisa

Team

Ad Honorem
Mar Medina, Javier

Postdoctoral Researcher
Arrospide Elgarresta, Arantzazu
Etxebarria Foronda, Iñigo
Ibarrondo Olagüenaga, Oliver
Jauregui García, María Luz
Soto Ruiz De Gordo, Myriam



PROJECTS

Active projects
Public competitive programmes
International, 1
National, 1
Autonomous, 1
Total 3

Public competitive programme projects awarded
International, 1
Total 1

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



TRANSFER

Intellectual property registration:
1. Software for diabetic retinopathy screening.

Licensing agreement:
1. Software for diabetic retinopathy screening, licensed to ULMA MEDICAL TECHNOLOGIES S. Coop.

HIGHLIGHTED ARTICLES

01. Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C et al. IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease. Value Health. 2025; 28(4):497-510.
02. Mar Barrutia L, Larranaga I, Chart Pascual JP, Zorrilla I, Abejas Diez D, Gomez Prieto A et al. Short Research Article: Independent association between household income and family adversity and bipolar disorder in adolescence and young adulthood - a registry-data study in the Basque Country. Child Adolesc. Ment. Health. 2025; 30(4):392-396.
03. Zumeta Olaskoaga L, Ibarrondo O, Del Pozo R, Zapiain A, Larrañaga I, Mar J. The Excess Direct Social Costs of Dementia-Related Neuropsychiatric Symptoms: A Regionwide Cohort Study Beyond Silos. Value Health. 2025; 28(4):536-544.

6.7 Bioengineering Area

BIOENGINEERING AREA

Computational Biology and Systems Biomedicine

Bioengineering in Regeneration and Cancer

E-Health

Stem Cells and Ageing

Biosurfaces and Biomaterials

Scientific objectives and progress in 2025

The following monitoring objectives were successfully achieved during 2025:

- Promote the translational application of research results.
- Integrate various research groups within the area.
- Explore new inter-area research lines.
- Promote collaboration with international groups and/or organisations.
- Foster collaboration with the R&D&I ecosystem and the business network of the Basque Autonomous Community.
- Increase in the value of outputs transferred to the Research Results Transfer Office.
- Incorporate best practices aligned with RRI (Responsible Research and Innovation).

Most Notable Publications in 2025

Garcia Gonzalez MJ, Miranda JC, Sanjurjo JLR, Perez Herrera LV, Alvarez BC, Echeberria Barrio X et al. AUPA: weakly supervised approach for streamlining breast cancer diagnostic workflow by WSI histological type classification for efficient IHC triage. Sci Rep. 2025; 15(1):42115-42115.

Nogradi B, Molnar K, Kristof R, Horvath O, Huang Y, Ridgway Z et al. The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis. Nat Commun. 2025; 16(1):7053-7053.

Zamora P, Movellan J, Grande HJ, Loinaz I, Dupin D. Hydrophobically-modified hyaluronic acid as stabilizer for oil-in-water emulsions to improve epidermis biodistribution of actives. Int J Biol Macromol. 2025; 330(Pt 4):148329-148329.

Han D, Xu W, Jeong H, Park H, Weyer K, Tsytsyura Y et al. Multipotent neural stem cells originating from neuroepithelium exist outside the mouse central nervous system. Nat. Cell Biol. 2025; 27(4):605-618.

Garrido CA, Garske DS, Bucher CH, Amini S, Duda GN, Schmidt Bleek K et al. Anisotropic hydrogel degradation enhances 3D collective mesenchymal stromal cell alignment, mechanotransduction and osteogenic differentiation. Acta Biomater. 2025; 204386-403.



6.7.1

Bioengineering Area

Computational Biology
and Systems Biomedicine

HR

Manager

Araúzo Bravo, Marcos Jesús

Team

Senior Researcher

Gerovska, Daniela Ivanova
Knafo, Dina Shira

Permanent Clinical Researcher

Unzurrunzaga Altube, Maite

PhD Student

Bohoyo Bengoetxea, Julen
Fernández Moreno, Patricia

PROJECTS

Active projects
Public competitive
programmes

International, 1

National, 1

Autonomous, 8


Total 10

Public competitive
programme projects
awarded

Autonomous, 4

Total 2

SCIENTIFIC
OUTPUT



TRANSFER

Patent families:

1. Device for assessing functional capacity.

Licensing agreement:

1. Functional capacity analysis device, licensed to BIOLAN S.L.

HIGHLIGHTED ARTICLES

01.
Han D, Xu W, Jeong H, Park H, Weyer K, Tsytsyura Y et al. Multipotent neural stem cells originating from neuroepithelium exist outside the mouse central nervous system. Nat. Cell Biol. 2025; 27(4):605-618.
02.
ARAUZO MJ,GEROVSKA DI,MS,AK. Genetic-Epigenetic Regulatory Mechanisms of Extrachromosomal Circular DNA: Evidence for a Role in Aging and Age-Related Neurodegenerative Disorders. En:Decoding Aging and Neurodegeneration. 2025.
03.
Wunderlich F, Gerovska D, Delic D, Arauzo Bravo MJ. Protective Vaccination of Mice Against Blood-Stage Malaria Impacts Hepatic Expression of Genes Encoding Acute-Phase Proteins and IL-6 Family Members. Int. J. Mol. Sci. 2025; 26(7):

PARTICIPATION IN
CONFERENCES



6.7.2

Bioengineering Area

Bioengineering in
Regeneration and Cancer

AWARDED HR
POSITIONS

Public competitive
programmes



Scholarship

AWARD

Competitive Private



HR

Manager

Cipitria Sagardia, Amaia

Team

Postdoctoral Researcher

Aiestaran Zelaia, Irati
Mitxelena Iribarren, Oihane
Pardo Sánchez, Jose Miguel
Pineda Castillo, Sergio Andres
Salvador Moreno, Naïke
Yañez Feliu, Guillermo Antonio

PhD Student

Anut, Sophie Therese
Berasain Garmendia, Jone
Cárdenas Perez, Rocio
Fallert, Laura
Heras Manterola, Unai
Masetto, Laura

Lab Manager

Toledo Fernandez, Iune

PROJECTS

Active projects
Public competitive
programmes

International, 4
National, 1
Local, 2

Active projects
Private competitive
programmes

National, 2


Total 8

Public competitive
programme projects
awarded

International, 1
Autonomous, 1

Total 2

SCIENTIFIC
OUTPUT



PARTICIPATION IN
CONFERENCES



Presentations



Posters

TRANSFER

Patent families:

1. Alginate-based hydrogel compositions and their uses.

HIGHLIGHTED ARTICLES

01. Garrido CA, Garske DS, Bucher CH, Amini S, Duda GN, Schmidt Bleek K et al. Anisotropic hydrogel degradation enhances 3D collective mesenchymal stromal cell alignment, mechanotransduction and osteogenic differentiation. Acta Biomater. 2025; 204386-403.
02. Taubenberger A, Hutmacher DW, Cipitria A. Editorial special issue-Convergence of biomaterials science and cancer research. Biomater. Adv. 2025; 177214396-214396.
03. Bock N, Delbianco M, Eder M, Weinkamer R, Amini S, Bidan CM et al. A materials science approach to extracellular matrices. Prog. Mater. Sci. 2025; 149

TRAINING



Total doctoral theses defended



Internationally recognised theses

6.7.3

Bioengineering Area

E-Health

HR

Managers

Macia Oliver, Iván

Team

Postdoctoral Researcher

Beristain Iraola, Andoni
Bertelsen Simonetti, Álvaro
Cortés Acosta, Camilo Andrés
Garin Muga, Alba
Goikolea Vives, Ane
Hernandez Jimenez, Mikel
López Linares Roman, Karen
Martin Andonegui, Cristina

Permanent Clinical Researcher

Comba Miranda, Jhon William
Del Cura Rodriguez, Jose Luis
García Familiar, Ainhoa
Marquina González, Ruth


PhD Student

Garcia Gonzalez, Maria Jesus
Kerexeta Sarriegi, Jon
Perez Herrera, Laura Valeria

Senior Research Technician

Sucre Rodríguez, Aurora María

SCIENTIFIC
OUTPUT



HIGHLIGHTED ARTICLES

- 01.**
Garcia Gonzalez MJ, Miranda JC, Sanjurjo JLR, Perez Herrera LV, Alvarez BC, Echeberria Barrio X et al. AUPA: weakly supervised approach for streamlining breast cancer diagnostic workflow by WSI histological type classification for efficient IHC triage. Sci Rep. 2025; 15(1):42115-42115.
- 02.**
Hernandez M, Osorio Marulanda PA, Catalina M, Loinaz L, Epelde G, Aginako N. Comprehensive evaluation framework for synthetic tabular data in health: fidelity, utility and privacy analysis of generative models with and without privacy guarantees. Front. Digit. Health. 2025; 71576290-1576290.
- 03.**
Asti G, Delleani M, Apellaniz P, Isasa I, Duarte DM, Galende BA et al. Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases. Blood. 2025; 1464350-4351.

CLINICAL TRIALS

Clinical Research

Clinical trials with medicinal products (MPs), **0**
Clinical research with medical devices (MDs), **1**
Observational studies (with MPs and MDs), **0**

Total active clinical studies **1**

TRAINING

1
Total doctoral theses defended

6.7.4

Bioengineering Area

Stem Cells and Ageing

HR

Managers

Alonso Martín, Sonia
Izeta Permisán, Ander

Team

Senior Researcher

Postdoctoral Researcher

Daou, Bahaa
Elicegui Aguirre, Amaia
Fuentes Álvarez, Sandra
García Puga, Mikel
Pikatzá Menoio, Oihane
Riestra Ayora, Ana Cristina
Solé Cañadas, Carla
Soutdjou, Haser Hasan
Vildosola Esturo, Susana

Permanent Clinical Researcher

Bonilla Zagala, Mario
Jimeno Badiola, María Begoña
Ormaechea Pérez, Nerea

PhD Student

Alonso Álvarez, Pedro
Arriola Álvarez, Inazio
Azcue Juaristi, Ignacio
Pikatzá Menoio, Oihane
Vidal Gil, Ainhoa

Senior Research Technician

Irastorza Lorenzo, Ainhoa
Hernandez Montalvo, Nora
Salcedo Vera, Juan Manuel
Yndriago Acha, Laura

Laboratory Technician

Levchuk, Mariya

PROJECTS

Active projects
Public competitive
programmes

International, 2

National, 5

Autonomous, 10

Total 17

Public competitive
programme projects
awarded

International, 1

National, 1

Autonomous, 6

Local, 1

Total 9

SCIENTIFIC
OUTPUT

15

Total
publications

12

Citable

67%

Q1

33%

D1

25%

Leadership

83%

Open
access

HIGHLIGHTED
ARTICLES

01.

Nogradi B, Molnar K,
Kristof R, Horvath O,
Huang Y, Ridgway Z et
al. The CCL2-CCR2 axis
drives neuromuscular
denervation in
amyotrophic lateral
sclerosis. Nat Commun.
2025; 16(1):7053-7053.

02.

Daou B, Prato M,
Alonso Martín S,
Alegret N. Carbon
Nanotube Hydrogels
Reveal Threshold-
Dependent Regulation
of Neuroblastoma Cell
Growth and Maturation
by Mechanical and
Chemical Factors.
Small Sci. 2025;
5(11):2500401-
2500401.

03.

Mosqueira Martín L,
Prendes García C,
Vesga Castro C, Marco
Moreno P, Irastorza A,
Izeta A et al. Validation
of an in vitro muscle
platform to evaluate
myogenesis and calcium
handling in control
and dystrophic human
myotubes. Sci Rep.
2025; 16(1):1891-1891.

TRANSFER

Patent families:

1. Method and device for detecting hypoxia.
2. Portable bioprinter with sterile chamber.
3. Development of customised bioinks based on nanoparticles for the 3D printing of dynamic breast cancer models.
4. Development of cartilage and tympanic membrane grafts using 3D bioprinting.
5. FOXO inhibitors: A new treatment for Amyotrophic Lateral Sclerosis (ALS).

Licensing agreement::

1. Method and device for detecting hypoxia, licensed to the institute's spin-off, OPTEC4LIFE S.L.
2. FOXO inhibitors: a new treatment for amyotrophic lateral sclerosis (ALS), licensed to MIAKER DEVELOPMENTS S.L.

Start up:

1. MIAKER DEVELOPMENTS S.L.

PARTICIPATION IN CONFERENCES

23

Presentations

16

Posters

TRAINING

4

Total doctoral
theses defended

2

Internationally
recognised theses

6.7.4

Bioengineering Area

Biosurfaces and Biomaterials

HR

Managers

Loinaz Bordonabe, Iraida
Dupin, Damien

Team

Postdoctoral Researcher

Alkorta Salegi, Janire
Cortizo Lacalle, Diego
De Souza Nunes, Juliana
Gutiérrez Pérez De Eulate, Natalia
Palla Rubio, Beatriz
Salvador Ditrich, Cristian

PhD Student

Wolfgang Etzold, Oliver

Laboratory Technician

Perez Fernandez, Raquel

PROJECTS

Active projects
Public competitive programmes

International, 1

Autonomous, 1

Total 2

Public competitive programme projects awarded

Autonomous, 1

Total 1

SCIENTIFIC OUTPUT



PARTICIPATION IN CONFERENCES



HIGHLIGHTED ARTICLES

- 01.** Zamora P, Movellan J, Grande HJ, Loinaz I, Dupin D. Hydrophobically-modified hyaluronic acid as stabilizer for oil-in-water emulsions to improve epidermis biodistribution of actives. Int J Biol Macromol. 2025; 330(Pt 4):148329-148329.
- 02.** Movellan J, Murgia X, Gracia R, Marradi M, Miranda JI, Aizpurua JM et al. Tobramycin nanoformulation for chronic pulmonary infections: From drug product definition to scale-up for preclinical evaluation. Int J Pharm. 2025; 671125241-125241.

6.8

Non-prioritised area

Associated Clinical Group


HIGHLIGHTED ARTICLES

01.
Resanoa M, Delgado A, Rodiño C, Villar M, Aiastui A, Braza MS. In the diffuse large B-cell lymphoma microenvironment, autophagy genes are upregulated in pro-inflammatory macrophages and linked to BCL2 overexpression. Front. Immunol. 2025; 161676563-1676563.
02.
Pineiro L, Idigoras P, Manzanal A, Ansa I, Vicente D. Mycoplasma penetrans urethritis in men. A case-control study. Front. Microbiol. 2025; 161565685-1565685.
03.
Castiella A, Sánchez Iturri MJ, Stampa J, Fernandez B, Garaizabal I, Prada A et al. Identifying patients with undiagnosed primary biliary cholangitis using a clinical management process. Ann Hepatol. 2025; 30(2):101933-101933.
04.
de la Riva P, Rodriguez Antigüedad J, Marta Enguita J, Gomez V, Arenaza G, Gorostidi A et al. The role of endothelial dysfunction in the age-related poor prognosis of stroke patients undergoing endovascular treatment. J. Stroke Cerebrovasc. Dis. 2025; 3
05.
Zabaleta J, Aguinagalde B, Lopez I, Fernandez Monge A, Lizarbe JA, Mainer M et al. Utility of Artificial Intelligence for Decision Making in Thoracic Multidisciplinary Tumor Boards. J. Clin. Med. 2025; 14(2):

PROJECTS


- 36
Total number of active projects in 2025
- 97
Total number of active clinical trials in 2025

SCIENTIFIC OUTPUT




TRANSFER

- Patent families:**
- 1. Portable device for exercising bedridden patients.
 - 2. ELOVL6 ELA Biomarker



Financial Data



Financial Data

This includes not only the accounts of the Biogipuzkoa Health Research Institute Association, but also those of the Biogipuzkoa HRI as a whole (same procedure as for the Executive Committee and General Assembly).

• Income	€19,550,342.00
• Contributions from corporate entities	€6,379,665.00
• External funding	€13,170,677.00
• External competitive funding	
• External non-competitive funding	
• External funding through billing of R&D&I services	

Income linked to indirect costs comes from three funding sources:

• Projects	
• Donations	
• Service provision	
• Total linked income Indirect costs	€1,175,342.02

• Expenses	€19,676,652.00
• Operating expenses	
• Personnel expenses	
• Depreciation of fixed assets	

The use of indirect costs is intended for:

1. Structural operating expenses, main items:
 - a) Provision of consultancy, prevention and communication services.
 - b) Inventory-related items.
2. Personnel expenses for administration, platforms and research support (not funded through competitive calls/other grants/billing of R&D&I services).

Details of income from corporate entities

Donostialdea IHO (Osakidetza-SVS), BIOEF, University of the Basque Country-Euskal Herriko Unibertsitatea.


Key areas:

- Donostialdea IHO
 - Operations and Staff
- Health Department
 - Registered Grant (Strategic Grant Plan)
 - Medtech Initiative
- Ikerbasque Foundation
 - Staff (Framework Collaboration Agreement)

Balance sheet

ASSETS	31/12/25	31/12/24
A) Non-current assets	19,683,242.00	19,290,093.50
B) Current assets	25,256,431.00	21,133,765.81
TOTAL ASSETS	44,939,673.00	40,423,859.31
	4,515,813.69	6,287,595.38
LIABILITIES	31/12/25	31/12/24
A) Net equity	9,551,954.00	9,048,155.65
B) Non-current liabilities	2,842.00	231.16
B) Current liabilities	35,384,877.00	31,375,472.50
TOTAL NET EQUITY AND LIABILITIES	44,939,673.00	40,423,859.31

Innovation



Innovation

Renewal as a Funded Unit of ITEMAS PT23

New unit structure with:


ASSOCIATED UNITS




TECHNOLOGY CENTRES



Strategic lines for promoting innovation




TECHNOLOGY TRANSFER



Tools to foster innovation

MEDTECH INITIATIVE



"BONO FOMENTO" FUNDING INSTRUMENT



BOTTOM UP



➔ Technology portfolio

Innovation conferences

DATOSXSALUD CONFERENCE:

A space for training, discussion, and experimentation open to the public, resulting from a collaboration between Biogipuzkoa, DIPC, the Donostia-San Sebastián Social Council, and Tabakalera on the secondary use of health data in research and innovation.

September 2025



GIPUZKOA INNOVATES IN HEALTH II:

Biogipuzkoa and the Donostialdea IHO brought together around 200 healthcare professionals from the Gipuzkoa IHOs, focusing on the importance of fostering a culture of innovation in healthcare.

November 2025



Communication



Communication

SOCIAL MEDIA

	 LinkedIn	 Facebook	 Instagram
Followers	8,305	1,067	1,221
vs 2024	+22%	+1%	+38%
No. of posts/stories/reels	407	470	375
Impressions	458,831	52,980	382,920
vs 2024	+29%	+0%	+201%
Total interactions (likes, comments, retweets)	46,329	3,394	6,101
vs 2024	+52%	-11%	+33%

FEATURED POSTS 2025



bto
8.991 seguidores
9 meses • 🌐

📍 Nuestra compañera **Leire Bejarano Bosque** ha obtenido una prestigiosa ERC Starting Grant, del Consejo Europeo de Investigación (**European Research Council (ERC)**) para desarrollar en **Biogipuzkoa** el proyecto **#METAVASC**, centrado en describir los determinantes vasculares que explican el desarrollo de la **#MetástasisCerebral**.

👉 Con una financiación de 1.499.500 € para los próximos 5 años, este proyecto innovador estudiará el papel de los componentes vasculares en fases tempranas y avanzadas de la enfermedad, con el objetivo de trasladar el conocimiento a la práctica clínica.

Estamos muy felices y orgullosos/os por nuestra compañera y con ganas de acompañarla en este viaje. 🇪🇺 **Zorionak Leire!**

👉 <https://lnkd.in/e-aybMwv>


Osakidetza OsasunE/GV




bto
BIOGIPUZKOA
ERUSKAL
OSASUN
IKERUNTZA
INBESITIGAZI
ON
VASKULO
BARIK
RESEARCH

Platform	Impressions	Engagement (Likes + Comments)
LinkedIn	12,790	6
Instagram	7,554	1

THE MEDIA



Percentages vs 2023

WEBSITE

Responsible Research and Innovation (RRI)



Responsible Research and Innovation (RRI)



ASSOCIATIONS AND CITIZEN PARTICIPATION



Ademgi
Nagusilan
Begisare
Adinpart
fshd spain
Asem
Colaboración
Participación en los órganos del instituto
Contra el Cáncer Gipuzkoa
Mas que ideas
Hoja de ruta
Atubivi
Ciudadanía
Formación
Aubixa
Katxalin



ACTIVITIES WITH OTHER ORGANISATIONS

7

Activities

40

Participating staff

248

Dissemination



dss week inn



SCIENTIFIC EDUCATION

5

Activities



27

Sessions

724

Participants

GENDER EQUALITY IN SCIENCE



PLAN DE IGUALDAD

¿Por qué?

10 ejes y acciones

comision.igualdad@bio-gipuzkoa.eus



10



BIOGIPUZKOA

EUSKAL
OSASUN
IKERKUNTZA
VASCA
EN SALUD
BASQUE
HEALTH
RESEARCH

Scientific
Report
2025



Paseo Dr. Begiristain, s/n
20014 Donostia-San Sebastián
+34 943 00 60 12
biogipuzkoa@bio-gipuzkoa.eus
www.biodonostia.org